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Chapter 1: Introduction 
 
1.1 Normal Mammary Gland Development 
1.1.A Overview of the mammary gland.  
The mammary gland is a complex secretory organ comprised mainly of 
epithelial cells, adipocytes, and stroma. In a normal, mature mammary gland, 
epithelial cells make up the branching network of ducts that ultimately functions 
in the delivery of milk to young. This ductal network is embedded within the fat 
pad. Surrounding each ductal branch is a thin basal lamina and a fibroblast-rich 
stromal compartment. Additionally interspersed throughout the mammary gland 
are blood and lymph vessels and an assortment of immune cells. Development 
of the mammary gland has been well studied predominantly through the use of 
mouse and rat models. While there are some differences between human and 
rodent mammary gland development, the most notable example being the 
number of mammary gland pairs that develop, animal models have provided vast 
insight into the intricate events that must take place in the life of a mammary 
gland and will be the focus of this section. The mature mammary gland develops 
through a tightly coordinated series of events that occur in three distinct stages: 
during embryogenesis, at puberty, and throughout adulthood.  
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1.1.B Embryonic development.  
At E10.5 in the mouse embryo, formation of a mammary (or milk) line on 
each side of the body in an anteroposterior direction between the limb buds 
marks the first step in mammary gland development [1, 2]. Along each mammary 
line, five mammary placodes, thick plate-like structures which are commonly 
found in development as the origins of specialized organs or tissues, begin to 
form at E11.5 [2-4]. Placode formation occurs in a tightly regulated and ordered 
fashion, such that the third thoracic placode appears first followed by the fourth 
inguinal placode before simultaneous formation of the first cervical and fifth 
inguinal placodes and finally the second thoracic placode appears. Studies 
suggest that these placodes arise from ectodermal cells migrating along the 
mammary lines [1, 2]. By E13.5, these placodes become the mammary buds as 
the epithelial cells of the placodes rapidly proliferate and invade into the 
underlying mesenchyme. The mammary buds continue to elongate into what are 
termed the mammary sprouts and signal to the surrounding mesenchyme via 
parathyroid hormone-related protein (PTHrP) to become mammary 
mesenchyme, without which mammary bud elongation into the sprout structure 
and further proper mammary gland development does not occur [5-7]. Within the 
mammary sprouts, epithelial cell apoptosis produces a hollow lumen around 
E15.5 that is connected to the developing nipple. By E18.5, the mammary 
sprouts have branched into rudimentary ductal trees containing between 10 and 
20 small branches. Each branch consists of a single layer of epithelial cells 
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surrounding a lumen. This ductal structure grows into white adipose tissue that 
has started to accumulate, which functions to support and eventually restrict the 
growth and branching of the ductal epithelial cells [8, 9]. This simple mammary 
gland consisting of a small epithelial ductal tree embedded within adipose tissue 
will cease to undergo further development until puberty. However, it will increase 
in size to keep pace with the body as it grows in size.  
 
1.1.C Pubertal development.  
At puberty, the mammary gland ductal network undergoes rapid, extensive 
growth and expansion. In mice, club shaped structures known as the terminal 
end buds (TEBs), appear at the tips of the primary epithelial ducts. In humans, 
these structures are called terminal duct lobular units (TDLUs). The TEBs are 
comprised of an outer layer of cap cells and multiple inner layers of body cells. 
Studies have proposed that the cap cells at the tip of the TEB are the 
undifferentiated mammary stem cells as they undergo both symmetric division to 
regenerate cap cells and asymmetric division to give rise to transit cells and have 
also been seen to migrate into the central layers of cells [10, 11]. Transit cells are 
bipotent progenitor cells. The outer layer of transit cells will differentiate into a 
myoepithelial lineage, while the inner transit cells (the body cells) will first 
transition into early luminal progenitors, then to late luminal progenitors, and then 
finally become the differentiated luminal epithelial cells. As the TEB progresses 
through the fat pad, the bulk of the luminal epithelial cells in the TEB will undergo 
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apoptosis [12]. The resultant ducts have a single layer of myoepithelial cells 
encompassing a single layer of luminal epithelial cells which are surrounding a 
hollow lumen. 
Expansion of the ducts is driven by the TEBs and ceases when the TEBs 
reach the outer edges of the mammary fat pad and regress into a mitotically 
inactive state. Along with ductal expansion, primary bifurcation occurs at the 
TEBs to give rise to new primary ducts. Along the primary ducts, secondary 
branches will sprout off laterally to fill in the fat pad. 
Unlike embryonic mammary ductal branching, which is apparently 
hormone independent, branching of the adolescent mammary gland transpires 
due to the production of hormonal signals from the ovaries and pituitary gland. 
Estrogen, estrogen receptor α (ERα), and growth hormone (GH) are all required 
for proper mammary ductal morphogenesis [13-17]. In addition to hormonal cues, 
localized growth factor signaling is also necessary for proper mammary ductal 
morphogenesis. Several growth factors or growth factor receptors, including 
epidermal growth factor receptor (EGFR, also known as ErbB1), amphiregulin 
(AREG), ErbB2 (also known as HER2 or neu), insulin-like growth factor 1 (IGF-
1), transforming growth factor α (TGFα), and numerous members of the fibroblast 
growth factor (FGF) family, have been shown to play important roles in proper 
mammary gland ductal morphogenesis at puberty [18-25]. 
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1.1.D Development during adulthood/pregnancy.  
During adulthood, the mammary gland undergoes tertiary branching and 
the formation of alveolar buds at the ends of these branches in response to the 
cyclical release of ovarian and pituitary gland hormones progesterone (P) and 
prolactin (Prl), respectively. The alveolar buds will eventually become 
differentiated alveoli, which are the sites of milk production and secretion, but this 
only occurs during pregnancy-induced growth of the mammary gland [26]. 
Studies have also demonstrated the requirement of both the P receptor (PR) and 
the Prl receptor (PrlR) in the formation of the tertiary branches and alveoli [27-
29]. During pregnancy, the mammary gland undergoes extensive ductal epithelial 
cell proliferation and increased tertiary branching to prepare for lactation. 
Additionally, alveologenesis occurs, such that the alveolar buds differentiate into 
individual alveoli. Within each alveolus, a single layer of alveolar epithelial cells 
form a spherical structure around a hollow lumen. While the luminal epithelial 
cells of ducts are encompassed within a continuous layer of myoepithelial cells, 
the myoepithelium of the alveoli is discontinuous, leaving some luminal cells in 
direct contact with the basement membrane. It is thought that this is important for 
successful milk secretion [30, 31]. Late in pregnancy, the mammary gland is 
almost completely filled with alveoli and milk production begins. Parturition marks 
the beginning of lactation, which will continue until weaning. Following weaning, 
massive involution of the differentiated alveoli via apoptosis and restructuring of 
the gland back to its pre-pregnant state occurs, signaled in part via signal 
  6 
transducer and activator of transcription 3 (STAT3) [32-34]. Upon completion of 
the involution process, the mammary gland resumes responding to cyclical 
steroid hormone signals and may recommence lobuloalveologenesis at any time. 
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1.2 Breast Cancer 
1.2.A An overview of breast cancer.  
Breast cancer is a complex and heterogeneous disease. In humans, it is 
thought that the conventional site of breast cancer initiation is within the TDLUs 
when abnormal enlargement of TDLUs progresses to hyperplastic enlarged 
lobular units (HELUs), which are the first histologically identifiable premalignant 
lesions in breast tissue [35, 36]. It has been proposed that HELUs have the 
ability to advance into many other lesions, most commonly the atypical ductal 
hyperplasia (ADH), which is generally thought to be the precursor of ductal 
carcinoma in situ (DCIS) [36-38]. Malignant disease arises from DCIS when the 
basement membrane surrounding each duct is breached, thereby becoming an 
invasive ductal carcinoma [35, 36, 38]. Invasive ductal carcinoma, not otherwise 
specified (IDC NOS) is the most frequently observed pathologically classified 
type of breast cancer, accounting for about 80% of all breast cancer cases [39, 
40]. The second largest pathological category of breast cancer is invasive lobular 
carcinoma (ILC), which only represents approximately 10% of all breast cancers 
[39, 40]. The remaining 10% of breast cancers are clinically classified into many 
rarely observed types [40]. 
In the clinic, breast cancers are usually characterized for treatment by the 
presence or absence of the hormone receptors (HRs), ER and PR, and the 
growth factor receptor HER2, three of the most well-known drivers of breast 
cancer. Tumors that are found to be HER2+ are treated with therapies that 
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specifically target HER2, such as the HER2 monoclonal antibody trastuzumab 
[41-44]. Tumors that express ER are treated with the ER-specific inhibitor 
Tamoxifen [45-47]. Additionally, aromatase inhibitors, which indirectly inhibit ER 
function by blocking the production of the ER ligand estrogen, are used to treat 
patients that are ER+ and ER+/PR+ [45, 48, 49]. However, the subset of breast 
cancers that are HR-/HER2- (known as triple negative (TN)) do not have any 
currently available and widely used targeted therapies. Instead, women with TN-
designated tumors usually receive chemotherapy, such as Doxorubicin, 
Cyclophosphamide, Paclitaxel, Capecitabine, 5-fluorouracil, and Gemcitabine 
[50, 51]. However, not all patients respond well to therapies when given based 
solely on the presence or absence of the HRs and HER2, and the complexity and 
heterogeneity of breast cancer is not completely mimicked with these markers 
alone. Since the pioneering study by Perou and colleagues in 2000, much 
research has been done using microarray-based global gene expression profiling 
and has resulted in the identification of several molecular intrinsic subtypes of 
breast cancer [52-57]. Currently, there are six distinct breast cancer intrinsic 
subtypes based on molecular profiling: claudin-low, basal-like, HER2-enriched, 
normal breast-like, luminal A, and luminal B. Each subtype can be distinguished 
from the others based on gene cluster expression patterns. Additionally, it has 
been proposed that each subtype arises from distinct progenitors.  
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1.2.B The luminal A and luminal B subtypes.  
The luminal A and B tumors are thought to both arise from differentiated 
luminal cells of the mammary ducts and were originally characterized by and 
named for the high expression of genes commonly expressed in luminal cells 
[53, 54, 58, 59]. They are further closely associated because they are both 
generally HR+ but HER2- [53, 55, 57]. However, this is not an efficient method 
for identification of the luminal tumors as at least 20% and approximately 10% of 
all luminal B and luminal A tumors, respectively, do express HER2 [60]. 
Moreover, at least 5% of all luminal tumors are HR-, strengthening the need for 
classification of breast cancers based on gene cluster analysis instead of via 
individual biomarkers [60]. Indeed, using gene cluster signatures, distinction 
between the two luminal subtypes can be identified. Luminal A tumors have high 
expression of ER and ER signaling-related molecules, which might be why they 
respond so well to the standard endocrine therapy treatment of luminal tumors, 
and are also enriched for genes involved in fatty acid metabolism [55, 57]. 
Patients with luminal A tumors have a good overall survival prognosis and much 
longer metastasis-free survival than any other subtype [56, 61]. The luminal 
subtypes can also be distinguished based on their proliferation profiles. Luminal 
B tumors have high expression of genes involved in proliferation, including Ki-67 
and Cyclin B1, while luminal A tumors have low levels of the proliferation gene 
cluster [62, 63]. Importantly, as there is a need for biomarkers in the clinic, 
luminal B tumors can generally be identified by high Ki-67 and as HR+/HER2-, 
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while luminal A tumors are usually HR+/HER2- and low for Ki-67 [60, 62]. These 
data suggest that luminal B tumors are rapidly proliferating, which may account 
for the poor prognosis associated with this subtype [56, 62, 64].  
 
1.2.C The HER2-enriched subtype. 
HER2 overexpression occurs in 15-30% of all breast cancers [65, 66]. The 
HER2-enriched subtype of breast cancers is therefore justly named because of 
HER2 gene amplification as well as gene enrichment for HER2 downstream 
signaling molecules [53]. Interestingly, most of the genes within the expression 
profile for this subtype are located near HER2 on chromosome 17 and are also 
amplified [53, 67]. However, around 35% of tumors in this category do not 
actually contain HER2 overexpression, and it has been proposed that the HER2-
enriched tumors that are HER2- might have a mutation that phenotypically 
mimics HER2-amplification/signaling [60]. Surprisingly, although there is a clear 
target for directed therapy in this subtype, not all patients respond well to 
trastuzumab treatment. In fact, the HER2-enriched subtype consistently shows 
the worst overall and disease-free survival of all the intrinsic subtypes [55, 56, 60, 
68]. On the other hand, trastuzumab in conjunction with chemotherapy has 
yielded better overall and recurrence-free survival, perhaps owing to the fact that 
HER2-enriched tumors are usually highly proliferative [69, 70]. The HER2-
enriched intrinsic subtype appears to arise from a late luminal progenitor [59].  
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1.2.D The basal-like subtype. 
The basal-like subtype comprises 15-25% of all breast cancers and largely 
consists of TN breast cancers (TNBCs) [53, 60, 71, 72]. Because of a lack of 
conventional targets in this subset, basal-like tumors are usually treated with 
chemotherapies [50, 51]. However, approximately 20% of all basal-like tumors 
remain ER+ and/or HER2+ [60]. Therefore, the use of only ER/PR/HER2 
negative status is not entirely consistent with the basal-like tumor subset, and 
some studies have suggested a five gene signature for better identification of this 
subtype in the clinic. The five marker method, or Core Basal group, includes ER-, 
PR-, and HER2- in addition to EGFR and cytokeratin 5/6 as positive markers and 
has been shown to more accurately identify a tumor as basal-like [68, 73]. 
Interestingly, results using the five marker method have demonstrated that basal-
like tumors that are TN, EGFR+, and cytokeratin 5/6+ (Core Basal) have worse 
prognosis than TN, EGFR-, and cytokeratin 5/6- tumors (5 Negative Profile) [68]. 
Basal-like tumors are highly mitotically active, often aggressive tumors that are 
most frequently found in younger, premenopausal patients [71, 72, 74-76]. In 
general, basal-like tumors initially respond well to chemotherapeutic treatment, 
but most women do not have complete pathological response, ultimately 
resulting in high early relapse rates and low overall survival [50, 51, 56, 77-79]. It 
is thought that basal-like tumors arise from luminal progenitor cells as they have 
the highest expression of a characteristic set of genes expressed in the luminal 
progenitor population [58, 59]. Additionally, gene profiling of basal-like tumors 
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shows that they also highly express genes involved in angiogenesis, cell cycle 
regulation, proliferation, and cell motility [57, 80].  Interestingly, breast cancers 
with the hereditary BRCA1 gene mutation are usually found in the basal-like 
subset of breast cancers [56, 58, 81].  
 
1.2.E The claudin-low subtype. 
The most recently identified breast cancer subtype is the claudin-low 
tumors [52, 54]. As indicated by the name, one of the characteristic gene 
signatures of the claudin-low tumors is relatively low expression of a series of 
proteins known for their role in cell-cell adhesion, including claudin 3, claudin 4, 
and claudin 7 [52, 54]. Alternatively, claudin-low tumors express high levels of a 
gene cluster consisting of mesenchymal/extracellular matrix genes and another 
gene cluster composed mainly of immune system response genes [54, 82, 83]. It 
is not yet known to what extent the actual tumor cells express the immune 
system response genes versus the possibility that there are simply high levels of 
immune cells infiltrating this tumor subtype. High expression of mesenchymal-
related genes has been proposed to be characteristic of the mammary stem cell 
population, and it is thought that the claudin-low tumors arise from a stem cell or 
stem cell-like population of cells [58, 59, 84, 85]. In favor of this notion, claudin-
low tumors express high levels of the mesenchymal proteins vimentin, N-
cadherin, and TWIST1 and the stem cell(-like) marker aldehyde dehydrogenase 
1 (ALDH1) [54]. Additionally, claudin-low is the only breast cancer intrinsic 
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subtype to express a signature gene expression profile previously implicated to 
specify breast cancer stem cells [82, 86]. Several studies have suggested that 
stem cells are chemoresistant and therefore relapse occurs because, while the 
bulk of the tumor responds to chemotherapy, the end result is enrichment of the 
cancer stem cells and an ultimately more aggressive disease [84, 86-88]. As the 
majority of claudin-low tumors are TN tumors, the current standard treatment 
plan for these patients is chemotherapy [50, 51, 54]. Indeed, claudin-low tumors 
treated with chemotherapy show low pathological complete response as 
compared to basal-like tumors, suggesting that they are relatively chemo-
insensitive [60]. In addition, patients with claudin-low tumors have poor overall 
and relapse-free survival, further supporting that claudin-low tumors arise from a 
stem cell(-like) progenitor [54, 59, 60].  
 
As evidenced by the data collected in just the last decade, breast cancer 
is a complicated and intricate set of diseases. Clearly numerous pathways and 
molecules are involved in the initiation and progression of breast cancers. Much 
work is still needed to better understand which factors might represent valuable 
targets for new therapies, to develop new therapies, and to determine when such 
new therapies will be of benefit to patients. The following sections will introduce 
the proteins that have been the focus of my thesis research.  
  
  14 
1.3 Fibroblast Growth Factor Receptor 1 
1.3.A The fibroblast growth factor family. 
The fibroblast growth factor (FGF) family is comprised of 22 structurally 
similar ligands and four membrane-bound receptor tyrosine kinases. Each FGF 
receptor (FGFR) contains three extracellular immunoglobulin (Ig)-like domains, 
an acidic box, a transmembrane domain, and a split intracellular tyrosine kinase 
domain. Additionally, heparin or heparin sulfate proteoglycans have been shown 
to stabilize FGF to FGFR binding, and each receptor has an extracellular 
heparin-binding site [89, 90]. Complexity of the FGF family arises not only 
because each ligand can bind multiple receptors but also because FGFR1-3 
undergo alternative splicing. This alternative splicing usually occurs from the 
differential usage of two exons both coding for the C-terminal region of the third 
Ig-like domain resulting in either the IIIb or IIIc isoforms. These splice variants are 
expressed in different tissues and have different ligand binding specificities. 
Ligand binding to an FGFR monomer induces dimerization and subsequent 
transphosphorylation of tyrosine residues within the kinase domains. Adaptor 
molecules, such as FGFR substrate 2 (FRS2) or phospholipase Cγ (PLCγ), 
bound to the activated receptor dimer can then themselves be phosphorylated 
and activated and subsequently act to transmit the FGFR activation signal 
through a variety of downstream molecules, including phosphoinositide-3 kinase 
(PI3K), extracellular signal-regulated kinase 1/2 (ERK1/2), various signal 
transducer and activator of transcription (STAT) proteins, and protein kinase C 
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(PKC), to stimulate cellular processes such as proliferation, survival, migration, 
and angiogenesis. The FGF family has been widely studied and reviewed in 
normal and diseased processes [91-96]. 
 
1.3.B The FGF family in mammary gland development. 
FGF signaling has been linked to many developmental processes, 
including the formation of limb buds, stimulation of angiogenesis, and induction of 
branching morphogenesis in organs such as the kidneys, lungs, prostate, and 
mammary glands [97-104]. During embryonic mammary gland development, 
FGF10 and its receptor FGFR2-IIIb are essential for proper mammary placode 
formation [3, 105]. FGFR2 expression is also required within the mammary 
epithelium during pubertal ductal morphogenesis, as Cre-mediated removal of 
FGFR2-IIIb within the epithelium results in reduced ductal morphogenesis and a 
lack of TEBs [106]. Interestingly, while FGFR2 is expressed in the epithelial cells, 
its ligand, FGF10 is highly expressed in the mammary fat pad, suggesting a 
paracrine signaling axis [106]. Additional FGF ligands, FGF2 and FGF7, have 
also been shown to stimulate ductal morphogenesis in EGFR deficient mammary 
organoids grown in culture [107]. FGFR2-IIIb and EGFR are expressed and 
required in separate compartments in the mammary gland, suggesting that there 
may be crosstalk between the two signaling pathways and mammary gland 
compartments during proper mammary gland development. 
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1.3.C FGFR1 in breast cancer. 
Dysregulation of FGF signaling has been implicated in mammary 
tumorigenesis as well. Mammary tumor samples from mice harboring the mouse 
mammary tumor virus (MMTV) often show high rates of MMTV insertion 
upstream of FGF genes [108-110]. Aberrant expression of FGF3 in the mouse 
mammary gland also leads to hyperplastic lesions [111]. Overexpression of 
FGFR2 or FGFR4 is observed in a portion of breast cancer patients as well [112, 
113]. Additionally, amplification of the genomic region 8p11-12, which contains 
the FGFR1 gene, occurs in approximately 10% of breast cancers [114-117]. 
Much debate has ensued regarding whether FGFR1 is actually the oncogenic 
driver of the 8p11-12 amplification as some studies have found that FGFR1 is not 
always contained within the amplified region [112, 118]. Work done by Gelsi-
Boyer and colleagues revealed that this debate has probably resulted because 
instead of one homogeneous amplicon, at least four different, only partially 
overlapping amplicons arise from this region. However, FGFR1 is indeed 
encoded within at least one of these amplicons [119]. Notably, patients harboring 
the FGFR1-containing amplicon have significantly worse metastasis-free 
survival, an increase in the development of distant metastases, shorter disease-
free survival, and decreased overall survival when compared to patients without 
the FGFR1 amplicon [116, 119-121]. Importantly, FGFR1 amplification has been 
associated with increased gene expression and protein overexpression [114, 
116, 119, 121, 122]. In breast cancer cell lines, amplification of FGFR1 promotes 
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anchorage-independent growth, and inhibition of FGFR1 with siRNA decreases 
cell viability, suggesting that aberrant FGFR1 signaling promotes tumorigenic 
phenotypes [121, 122]. FGFR1 amplification in primary breast tumors correlates 
with ER+ but PR- status, and 8p11-12 amplification is often found in the ER+ 
luminal A and luminal B type breast cancers [116, 120, 121]. Since luminal B 
tumors are highly proliferative, poor-prognostic tumors, these results indicate 
FGFR1 amplification might be an important occurrence of more aggressive 
breast cancers. In line with such a notion, breast cancer cell lines with FGFR1 
amplification display increased resistance to endocrine therapies [121]. 
Furthermore, recent work has revealed that FGFR signaling occurs in TN and 
basal-like breast cancers and inhibition of FGFR both in vitro and in vivo inhibits 
cell survival [123]. Some studies have also indicated that the 8p11-12 
amplification cooperates with other amplifications, such as 11q13, to promote 
tumorigenesis [122, 124-126].  
 
1.3.D The inducible FGFR1 system. 
While the work described above demonstrates the importance of FGFR1 
in breast tumorigenesis, especially because FGFR1 amplification occurs in 
patients with poor prognosis, there is no direct insight into how aberrant FGFR1 
expression promotes tumorigenesis in those studies. However, it is difficult to 
specifically study endogenous FGFR1 signaling because, while multiple FGF 
ligands can activate FGFR1, no FGF ligand exclusively binds to and only 
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activates FGFR1. Therefore, the Rosen laboratory engineered an inducible 
FGFR1 (iFGFR1) construct, which allows for the exclusive study of FGFR1 
signaling [127]. In this construct, the FGFR1 kinase domain is tethered to the 
plasma membrane via a myristylation sequence that replaces the extracellular 
ligand binding and transmembrane domains. Removal of the extracellular ligand 
binding domain eliminates interactions between endogenous FGF ligands and 
the iFGFR1 construct and allows for complete control over activation of iFGFR1. 
Dimerization and subsequent activation of the kinase domain is instead 
stimulated through a synthetic dimerization system affixed to the kinase domain. 
Thus, dimerization occurs upon treatment with the synthetic molecule, AP20187 
(AP, renamed B/B when bought by Clontech, Mountain View, CA, USA), which 
traverses the plasma membrane and binds the intracellular dimerization 
sequences of two iFGFR1 monomeric constructs, allowing for 
transphosphorylation of kinase domain tyrosine residues.  
To ensure that the iFGFR1 construct correctly mimicked endogenous 
FGFR1, the mouse mammary epithelial cell line, HC11, was retrovirally 
transduced to express iFGFR1. Analysis of the cells stably expressing the 
iFGFR1 construct, named HC11/R1 cells, confirmed that the iFGFR1 kinase 
domain, docking protein FRS2, and downstream signaling proteins Akt and 
ERK1/2 were all phosphorylated following treatment with AP [127]. These results 
demonstrate that iFGFR1 activation results in activation of endogenous signaling 
pathways. Functional studies showed that HC11/R1 cells treated with AP 
  19 
displayed increased motility and proliferation and decreased apoptosis when 
grown in a monolayer as compared to controls [127, 128]. Furthermore, AP 
treatment of the HC11/R1 cells grown in three dimensional culture resulted in 
increased acinar size, increased proliferation, acquired invasiveness, disrupted 
cellular polarity, and decreased apoptosis as compared to controls [128]. iFGFR1 
activation also resulted in increased expression of matrix metalloprotease 3 
(MMP-3) and E-cadherin cleavage, both of which are required for epithelial-to-
mesenchymal transition (EMT) to occur [128]. All together, these results indicate 
that activation of iFGFR1 in vitro promotes several cellular processes that are 
characteristically co-opted in tumorigenesis. 
In addition to the creation of the in vitro HC11/R1 cell line, the Rosen 
laboratory also generated iFGFR1 transgenic mice using MMTV to drive 
expression of the iFGFR1 construct in mammary epithelial cells [127]. While 
activation of iFGFR1 with intraperitoneal injections of AP did not result in gross 
morphological changes in ductal morphogenesis as compared to age-matched 
nontransgenic control mice, there was aberrant formation of lateral buds along 
primary, secondary, and tertiary ducts after only 48 hours of AP treatment [127, 
129]. Prolonged AP treatment led to more dense epithelial lateral budding and 
eventually to invasive, preneoplastic lesions most likely due to the detectable 
increase in proliferation in these mammary glands [127]. Similar to in vitro 
results, activation of iFGFR1 in vivo induced activity of MMP-2 and MMP-9, 
suggesting that extended iFGFR1 activation leads to increasingly invasive 
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properties [127]. Interestingly, it was also found that the iFGFR1-stimulated 
lateral budding and epithelial proliferation required the presence of macrophages 
[129]. The idea that recruitment of immune cells may be crucial for iFGFR1-
induced tumorigenic phenotypes is currently under further investigation. 
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1.4 Amphiregulin 
1.4.A Discovery and characterization of Amphiregulin. 
Amphiregulin (AREG) was originally discovered by Shoyab and 
colleagues attempting to identify proteins produced in response to the tumor 
promoting phorbol ester, phorbol 12-myristate 13-acetate (PMA), treatment of the 
human breast cancer cell line MCF7 [130]. Characterization of AREG revealed 
that it contains a characteristic set of six spatially conserved cysteine residues 
that interact and form disulfide bonds resulting in three structural loops essential 
for interaction with EGFR, thus identifying it as another member of the EGF 
family of ligands [131, 132]. AREG was confirmed as an EGFR ligand through 
competitive binding studies with 125I-EGF, where it was found to be able to 
partially compete with 125I-EGF for binding to EGFR [131]. Other studies 
demonstrated that AREG actually exclusively binds to and activates EGFR, 
although it can also activate the other ErbB receptors, ErbB2/HER2/neu, ErbB3, 
and ErbB4, in an EGFR-dependent manner, perhaps by promoting receptor 
heterodimerization [133-135]. In addition to its conserved EGF motif in the N-
terminal domain, AREG also contains a transmembrane domain characteristic of 
the EGF family of ligands and is initially synthesized as a 252 amino acid 
transmembrane precursor protein [132]. This precursor protein is usually cleaved 
from the membrane by a sheddase and released as a soluble, mature protein, 
whereby it exerts its activity in both autocrine and paracrine fashions, but it is 
thought that AREG may also be able to act in a juxtracrine manner [136-138]. 
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There are several isoforms of AREG due to post-translational modifications, 
however it is not known whether all of the isoforms contain biological activity or 
not [131, 139]. 
In humans, the gene encoding AREG is located on the long arm of 
chromosome 4 at 4q13-4q21 [132]. Within the AREG promoter, there are several 
possible transcription factor docking sites and responsive elements, including 
cyclic AMP (cAMP) responsive element, estrogen responsive element, serum 
responsive element, specificity protein 1 element, and Wilms’ tumor suppressor 
responsive element, suggesting that there may be multiple avenues of AREG 
expression regulation [132, 140-145]. The AREG transcript is 1.4kb and contains 
six exons. Exons one through three possess the 5’UTR, two putative nuclear 
localization signals, and two of the three disulfide loops. The third disulfide loop is 
located within the fourth exon, as is the transmembrane domain. The fifth exon 
contains the cytoplasmic domain, and the sixth exon includes the 3’UTR. The 
putative nuclear localization signals appear to be real, as AREG has been found 
via immunohistochemistry both in the cytoplasm and in the nucleus of some cell 
types, but it is yet to be determined whether AREG exhibits any nuclear 
biological function [131, 146, 147]. The C-terminal domain is essential for proper 
AREG membrane localization of the transmembrane precursor protein [148]. 
AREG transcript is expressed in many different tissues, including skin, ovaries, 
placenta, gastrointestinal tract, pancreas, kidney, lung, and mammary gland 
[132]. Within these tissues, AREG is involved in many different processes such 
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as epidermal hyperplasia, blastocyst implantation, nerve regeneration, and 
mammary gland development [19, 20, 149-153]. The role AREG plays in normal 
mammary gland development has been the most extensively studied.  
 
1.4.B AREG and its regulation in mammary gland development. 
Areg knockout (KO) mice have provided valuable insight into the role of 
AREG in the developing mammary gland. Luetteke and colleagues generated 
Areg, Egf, and Tgfα individual and combinatorial KO mice [20]. While triple KO 
animals were viable, healthy, and fertile, pups born to triple KO mothers were 
often runted or died shortly after birth with little or no milk spots, suggesting that 
the triple KO mothers possessed some sort of mammary gland defect. Upon 
comparison of pubertal triple KO mammary glands to wildtype (WT) mammary 
glands, it was found that the ductal trees of the triple KO glands had not 
progressed past the small embryonic ductal structures, while the WT glands had 
clearly undergone normal pubescent ductal elongation and branching. 
Additionally, WT glands contained many TEBs, but only a few TEBs were visible 
in the mammary glands of the triple KO animals. Furthermore, glands from 
double KO mice of both Egf and Tgfα, but retaining at least one copy of Areg, 
were comparable to glands from WT mice. However, while triple KO females also 
exhibited severe lobuloalveologenesis defects, Areg-only KO females were 
capable of undergoing lobuloalveolar proliferation and differentiation. In 
corroboration with the findings of Luetteke and collegues, Ciarloni and colleagues 
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also found that mammary gland development was similar in Areg-/- and WT mice 
up to puberty at which time WT glands underwent ductal morphogenesis but 
Areg-/- glands did not [154]. It was also found that TEB formation and ductal 
epithelial cell proliferation were abolished in Areg-/- animals, but that AREG 
depletion did not significantly affect lobuloalveologenesis. Moreover, chimeric 
transplantation of both WT and Areg-/- mammary epithelial cells into cleared 
mammary fat pads demonstrated the ability of AREG to act in a paracrine 
manner as Areg-/- cells were still able to proliferate as long as they were within 
close proximity to WT cells. Together these results suggest that AREG is the 
primary EGFR ligand responsible for normal ductal elongation but is not 
necessary for lobuloalveologenesis. Instead, other EGFR ligands, such as EGF 
and TGFα are important for lobuloalveologenesis. Work done by Kenney and 
colleagues supports the paracrine function of AREG in the mammary gland as 
exogenous AREG, administered by implantation of slow-release pellets, was able 
to reestablish ductal morphogenesis in ovariectomized mice [19]. To establish 
whether AREG is required in the epithelial or stromal compartment of the 
mammary gland, Sternlicht and colleagues performed mammary transplants 
using Areg-/- epithelial cells embedded in either WT or Areg-/-  fat pads or WT 
epithelial cells embedded in either WT or Areg-/-  fat pads [107]. While the WT 
epithelial cells were able to grow regardless of the stromal compartment 
genotype, the Areg-/- epithelial cells were unable to grow in either stromal 
compartment, suggesting that AREG is required in the mammary epithelium for 
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normal ductal morphogenesis. Recent studies have suggested that AREG might 
be such a potent growth factor in the mammary gland because it might mediate 
the growth and self-renewing capacity of a subset of mammary epithelial 
progenitor cells [155].  
In the normal developing mammary gland of the mouse, AREG is the only 
EGFR ligand to be highly expressed from the beginning of puberty at about four 
weeks to around 12 weeks of age, which coincides with the phase of highest 
mammary gland ductal morphogenesis [156]. At this time, estrogen production 
has also begun in the ovaries, suggesting that circulating estrogen may mediate 
AREG expression in the mammary gland. This notion was strengthened by the 
discovery of estrogen response elements within the Areg promoter region and by 
chromatin immunoprecipitation (ChIP) analysis showing direct ERα binding of the 
Areg gene [145, 157]. Additionally, estrogen treatment of the ERα-positive breast 
cancer cell line MCF7 stimulated increased AREG transcript and protein 
expression [158]. In vivo studies using Erα KO mice revealed that ductal 
morphogenesis of the mammary gland was severely stunted but could be 
rescued by exogenous AREG [15]. This impairment of ductal morphogenesis is 
mimicked in Areg KO mice [154]. Furthermore, it was found that Erα was 
required in the mammary epithelium, but dispensable in the stroma, for proper 
ductal morphogenesis [15]. Not only does the epithelial requirement of ERα 
correspond with Areg expression occurring exclusively in the mammary 
epithelium, but the ER transcriptional co-activator, CITED1, also has the same 
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expression pattern as Areg in the developing mammary gland [20, 157, 159, 
160]. Perhaps not surprisingly, Cited1 KO mice display the same ductal 
morphogenesis impairment as Erα KO and Areg KO mice, and AREG expression 
in the mammary gland is reduced in these animals [161]. It has also been shown 
that Erα-/- cells can proliferate when in close proximity to Erα+/+ cells much like 
Areg-/- mammary epithelial cells can proliferate if in close proximity to Areg+/+ 
cells, signifying that epithelial cell proliferation in the mammary gland is regulated 
in a paracrine fashion [15, 154].  
As previously stated, AREG initially exists as a transmembrane precursor 
protein that is usually subsequently cleaved from the membrane to exert its 
activity in an autocrine or paracrine manner. This is common amongst all EGF 
family ligands, and much work has been done to identify the enzymes 
responsible for this cleavage [162-164]. Because of their membrane bound 
nature, the a disintegrin and metalloprotease (ADAM) enzymes were attractive 
candidates for EGF family ligand release, and studies have demonstrated that 
ADAM17 (also known as tumor necrosis factor α (TNFα) converting enzyme 
(TACE) because it was originally discovered to cleave TNFα) is the primary 
AREG sheddase [107, 164-166]. Several lines of evidence give credence to the 
idea that ADAM17 is also required for proper mammary gland development. 
Adam17-/- pups have reduced numbers of ductal branches that are also shorter 
than their WT littermates, a similar phenotype to that observed in Egfr-/- 
mammary glands grown under the renal capsules of immuno-compromised host 
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animals [107, 167]. Additionally, like Areg, Adam17 expression was required in 
the mammary epithelial compartment, but not in the stroma, for proper mammary 
gland development [107]. Therefore, ADAM17 and AREG are expressed and 
essential in the same cells of the developing mammary gland, which is a vital 
feature for the membrane bound ADAM17 to be able to cleave the also 
membrane bound AREG precursor protein. Furthermore, a requirement for 
stromal EGFR, but not epithelial EGFR, has been identified in the mammary 
gland [107, 167]. As EGFR is the only AREG receptor, these findings augment 
the necessity for ADAM17 to cleave AREG from the mammary epithelial cells 
because the ductal epithelium and the stroma are separated from one another by 
a basement membrane in the mammary gland.  
In combination, these studies demonstrate that ERα is a direct mediator of 
AREG expression in mammary epithelial cells during the period of pubertal ductal 
growth and expansion. ADAM17 sheds AREG from mammary epithelial cells so 
that it can act in a paracrine fashion to induce ductal morphogenesis by 
activating its receptor, EGFR, in the stroma. It is not yet clear how EGFR 
activation in the stroma then regulates epithelial cell proliferation.  
 
1.4.C AREG in breast cancer. 
Because of its significant role in normal mammary gland development, 
AREG has attracted a lot of attention in the breast cancer field. In the normal 
developing mammary gland, Areg is expressed in the epithelial compartment 
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[107]. AREG has been found to remain localized to the epithelial tumor cells in 
breast cancers and to be upregulated in the preneoplastic HELU lesions relative 
to the normal TDLUs [168, 169]. Estrogen treatment of breast cancer cell lines 
can induce AREG transcript and protein expression in breast cancer cell lines, 
suggesting that ERα continues to be a mediator of AREG expression in breast 
cancers [158, 170, 171]. In line with such results, AREG often correlates with 
ERα and PR positivity in breast cancers [172, 173]. Interestingly, it has been 
shown that parity, a well-established protector of young women from breast 
cancer, reduces AREG expression [159]. As AREG is a growth factor, it is not 
surprising that it has been shown to stimulate proliferation of breast cancer cell 
lines [138, 174, 175]. Further demonstrating AREG’s ability to stimulate tumor 
growth, it was found that knockdown of AREG in the human breast cancer cell 
line NS2T2A1 resulted in significantly reduced tumor burden in xenograft mice 
[176]. Additionally, treatment of breast cancer cells with AREG induces increased 
expression of numerous genes involved in metastasis and invasion, most notably 
MMP-9 [138, 174, 177]. Furthermore, shRNA knockdown of AREG in human 
breast cancer cells reduced the ability of these cells to invade into a Matrigel 
matrix [178]. These results implicate AREG expression in more advanced or 
aggressive breast cancers, and indeed high AREG expression is commonly 
found in lymph node positive breast cancers and in invasive breast carcinomas 
[169, 179, 180]. Studies have also revealed that AREG appears to be involved in 
resistance to targeted therapies and chemotherapies in breast cancer, further 
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supporting the findings that AREG is linked to a more advanced disease state 
[145, 181, 182].  
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1.5 Epiregulin 
Epiregulin (EREG) was originally discovered in the conditioned media of 
the mouse tumorigenic cell line, NIH3T3/clone T7 [183]. Upon investigation into 
the sequence, a set of six spatially conserved cysteine residues, as well as a key 
leucine residue, were identified that marked EREG as the newest member of the 
EGF family of ligands [183]. In humans, the EREG gene is located on the long 
arm of chromosome 4 near the genes for AREG and betacellulin. Because of the 
close proximity of these genes, it has been suggested that gene duplication 
occurred at some point in evolutionary history [184]. Perhaps in favor of such an 
occurrence, characterization of EREG uncovered an N-terminal localization 
sequence, followed by the EGF domain containing the three loop structures that 
are the hallmark of the EGF family of ligands, followed by a transmembrane 
domain [185]. Thus, like all other EGF family ligands, EREG is initially 
synthesized as a transmembrane precursor protein. However, due to its 
discovery as a biologically active and mature protein in conditioned media, EREG 
must be shed from the plasma membrane. As other members of the EGF family 
of ligands are cleaved by ADAMs, the putative role of ADAMs in releasing EREG 
was determined [162, 166]. It is thought that ADAM17 might be the major EREG 
sheddase, although ADAMs 9, 12, and/or 15 also appear to be able to cleave 
EREG [164]. In its soluble form, EREG can bind to and activate both EGFR and 
ErbB4 [186, 187]. Even though it does not directly bind to HER2 and ErbB3, 
EREG does stimulate their phosphorylation, suggesting that EREG can promote 
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ErbB receptor heterodimerization [186, 187]. Interestingly, although structurally 
similar to other EGF family ligands, the expression profile of Ereg is not very 
comparable to the other members of the EGF family of ligands. While most EGF 
family ligands are fairly ubiquitously expressed, Ereg transcript expression is 
much more limited, detectable only in macrophages, the placenta, and during 
early embryogenesis [185, 188]. Because of its expression in the early mouse 
embryo, it was originally hypothesized that EREG might be a potent 
developmental regulator [185]. 
In spite of its limited expression in normal tissues, EREG has been shown 
to stimulate proliferation in a variety of cell types, including primary hepatocytes, 
mouse fibroblasts, keratinocytes, corneal epithelial cells, and vascular smooth 
muscle cells [183, 189-192]. It also promotes proliferation of pancreatic 
carcinomas, and EREG knockdown in conjunction with knockdown of N-RAS 
confers a decreased growth potential in human hepatoma cells [193, 194]. 
Furthermore, expression of EREG in oral squamous cell carcinomas has been 
linked to poor prognosis, and in non-small cell lung cancers (NSCLCs), EREG 
expression appears to be a marker for advanced disease state [195, 196]. While 
EREG has not been extensively studied in breast cancer, EREG expression has 
been identified as an indicator of poor prognosis for inflammatory breast cancer 
patients and to negatively correlate with HR+ breast cancers [172, 197]. Studies 
have also demonstrated that EREG can promote not only the proliferation of 
breast cancer cells but also their ability to metastasize to the lung when 
  32 
expressed with cyclooxygenase 2 (COX2), MMP-1, and MMP-2 [198, 199]. 
EREG also conferred an increased invasive potential in NSCLCs [195]. Together, 
these findings suggest involvement of EREG in cellular processes of 
proliferation, migration, and invasion.  
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1.6 Epidermal Growth Factor Receptor 
1.6.A The epidermal growth factor receptor protein. 
Epidermal growth factor receptor (EGFR) was originally discovered in the 
early 1980’s as a result of the ability of EGF to bind and initiate phosphorylation 
of EGFR [200, 201]. Since its discovery, it has been determined that EGFR is 
member of the ErbB family of receptor tyrosine kinases, consisting of 
ErbB1/EGFR, ErbB2/HER2/neu, ErbB3, and ErbB4. Each receptor contains an 
extracellular ligand binding domain, a transmembrane domain, and a tyrosine-
rich intracellular kinase domain. The extracellular ligand binding domain can be 
subdivided into four distinct regions: two large EGF binding domains and two 
cysteine-rich domains. Ligand binding induces a conformational change of the 
extracellular domain into what is called the extended confirmation. In the 
extended confirmation, the dimerization domain is exposed and both 
homodimerization and heterodimerization can occur. Dimerization allows the 
intracellular kinase domains of each monomer to stabilize and phosphorylate the 
other monomer’s kinase domain. Which tyrosine residues are phosphorylated is 
determined by which ligand induces dimerization and which monomers dimerize. 
Subsequent to autophosphorylation, downstream effector molecules containing 
either a Src-homology domain 2 (SH2) or a phospho-tyrosine binding (PTB) motif 
bind the intracellular domain. There are several such binding proteins, including 
Ras, Src, PI3K, Grb2, Cbl, PLCγ, which then further activate molecules like the 
STAT3 or STAT5 transcription factors, ERK1/2, or Akt. Through such signaling 
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pathways, EGFR activation mediates many different cellular processes, such as 
survival, migration, and proliferation, or events like receptor recycling and 
degradation. EGFR structure, activation, and signaling in normal and disease 
models has been extensively studied and reviewed [202-209]. 
 
1.6.B EGFR in normal mammary gland development. 
EGFR has long been known to play a role in normal mammary gland 
development. Characterization of waved-2 mice, which exhibit skin, hair, and eye 
abnormalities, led to the identification of a single nucleotide transversion within 
the kinase domain of EGFR, which resulted in reduced EGFR kinase activity 
[210, 211]. In addition to the obvious external phenotypes, waved-2 mice were 
also found to have impaired mammary gland development [211]. Moreover, 
whole mammary glands taken from Egfr-/- neonates and grown under the renal 
capsules of immuno-compromised mice displayed impaired mammary gland 
development [167]. In these glands, ductal growth and branching was severely 
reduced compared to WT glands, but lobuloalveolar development still occurred, 
suggesting that EGFR is only required during pubertal mammary gland 
development [167]. This is consistent with the necessity of the EGFR ligand, 
AREG, in the pubertal mammary gland [20, 154]. Although AREG is expressed 
and essential in mammary epithelial cells, much work has been done that 
demonstrates a stromal EGFR requirement. Mammary glands deficient for the 
AREG sheddase ADAM17 display stunted mammary ductal morphogenesis 
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similar to that seen in Egfr-/- animals, suggesting that AREG must be released 
from the epithelium to exert its activity [107]. Together with fact that the 
mammary epithelium and stromal compartments are separated by a basement 
membrane, these results are indicative of different compartmental requirements 
of AREG and EGFR. Additionally, EGFR is abundantly expressed in the 
mammary gland stroma, phosphorylated EGFR can be seen in the mammary 
stroma, and exogenous EGF can stimulate EGFR activation in epithelial cell-free 
mammary gland fat pads [18, 20, 212]. It has also been shown that EGFR is 
activated most highly in the stroma directly surrounding the TEBs, where ductal 
morphogenesis ensues [213]. While these studies imply that stromal EGFR is 
important, they do not show that EGFR is required in the stroma. However, 
studies performed using recombinant transplants of combinations of Egfr-/- and 
WT epithelium and stroma do provide direct evidence of a stromal EGFR 
requirement. While both Egfr-/- and WT mammary epithelium develop normal 
mammary gland ductal structures in WT fat pads, neither epithelial genotype 
undergoes ductal morphogenesis when transplanted into Egfr-/- fat pads [107, 
167]. Therefore, stromal EGFR is essential for mammary gland ductal 
morphogenesis, but is dispensable during lobuloalveolar development, and 
epithelial EGFR is not required for proper mammary gland development. How 
stromal EGFR regulates epithelial cell growth is still currently unknown, although 
it has been proposed that because growth factors such as hepatocyte growth 
factor (HGF), IGF-1, and FGF10 are all expressed in the stroma during ductal 
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morphogeneis, they may represent good candidates of EGFR-induced growth 
factor-mediated epithelial cell growth [154]. 
 
1.6.C EGFR in breast cancer. 
As a regulator of many cellular processes, including proliferation, survival, 
migration, invasion, and apoptosis, which are often dysregulated in the initiation 
and progression of cancer, an expansive amount of research has been done to 
examine EGFR in tumorigenesis, resulting in the identification of EGFR as a key 
factor in many types of cancer. Most notably, many gliomas present with EGFR 
overexpression and a mutant, constitutively active form of EGFR is often found in 
NSCLCs. EGFR has also been extensively investigated in breast cancer. Using 
transgenic animals with Egfr under the control of either the MMTV or the β-
lactoglobulin promoter, it has been shown that overexpression of EGFR in the 
mammary gland leads to epithelial hyperplasias in virgin mice which 
progressively worsen to dysplasias and tubular adenocarcinomas in mice that 
are lactating, with highest EGFR expression in the adenocarcinomas [214]. 
However, unlike in gliomas and NSCLCs, EGFR is rarely overexpressed or 
mutated in breast cancers, although it does appear to be expressed in 18-36% of 
all breast cancers [215-219]. Interestingly, owing to the fact that the EGFR ligand 
AREG is regulated by ERα in the mammary gland, many studies have found that 
EGFR positivity in breast cancer samples is inversely correlated with ER 
positivity [215, 216, 218, 220-222]. Alternatively, EGFR and HER2 expression 
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and phosphorylation appear to overlap in many primary breast tumors [223, 224]. 
While several studies have tried to determine whether EGFR could be used as a 
prognostic factor, the results have varied. Most studies found that EGFR is 
indicative of poor prognosis, and correlates with more aggressive or advanced 
disease [215, 216, 218, 220, 225-227]. In support of these findings, EGFR 
expression and activation has been linked to increased migration, which is a 
defining feature of more advanced disease [228-230]. Other studies have 
identified no link between EGFR status and prognosis or even favorable 
prognosis with EGFR expression [217, 223, 231]. The discrepancies of these 
studies may be the result of the various techniques or antibodies used to 
determine EGFR expression or perhaps because of having been done before the 
relatively recent categorization of breast cancer into several subtypes based on 
molecular profiling. Since the advent of breast cancer as multiple distinct 
diseases, EGFR expression has been indicated to occur in 50-70% of basal-like 
and/or TNBCs [72, 232]. In fact, EGFR has been proposed to be a marker of 
basal-like breast cancer, and studies have indicated that basal-like tumors that 
are EGFR+ have a worse prognosis than TN basal-like tumors [68, 73]. The 
connection of EGFR with basal-like/TNBCs is important as these cancers 
currently lack targeted therapies but often do not respond well to chemotherapy 
regimens, and clinical trials have commenced to determine whether EGFR 
inhibitors are of benefit to patients undergoing chemotherapy [50, 51]. 
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1.7 Signal Transducer and Activator of Transcription 3 
1.7.A Signal transducer and activator of transcription 3 discovery, 
structure, and activation. 
Signal transducer and activator of transcription 3 (STAT3) was originally 
discovered almost 20 years ago now as an acute phase response factor (and 
thusly originally named APRF) following interleukin 6 (IL-6) stimulation of 
hepatoma cells [233]. It was found that APRF binds IL-6 response elements on 
DNA and regulates transcription of several IL-6 target genes [233, 234]. Cloning 
of APRF identified it as a STAT protein due to high sequence and domain 
homology with and a similar expression pattern to STAT1 [235, 236]. The STAT 
family of proteins is now comprised of seven factors that, like the name suggests, 
relay signals through their transcription factor activity. Sequence comparisons, 
mutagenesis studies, and crystallography data have together established the 
structure and modularity of the STAT proteins [237-240]. The amino terminus of 
each STAT appears to function in stabilizing dimer:dimer interactions on DNA for 
transcriptional activation [241]. Tetrameric formation of the STATs on adjacent 
STAT-binding sites strengthens STAT:DNA binding and subsequent transcription 
[242-244]. Other studies have found additional roles of the amino terminus, 
including regulation of nuclear transport and subsequent dephosphorylation [245, 
246]. Following the amino terminus, there is a coiled-coil domain that appears to 
be involved in protein:protein interactions. The DNA binding domain resides in 
the middle of each STAT molecule followed by a linker domain that possibly 
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reinforces STAT:DNA binding [247]. The SH2 domain of each STAT protein then 
precedes the transactivation domain (TAD) at the C-terminus. The SH2 domain 
is required for STATs to interact with activated receptors for successive 
activation and for successful STAT dimerization. Between the SH2 domain and 
the TAD, lies the critical tyrosine residue of each STAT protein. This is tyrosine 
705 in STAT3 molecules. Additional phosphorylation at a serine residue (serine 
727) may be important for maximal transcriptional activity [248]. The TAD 
interacts with co-activators such as p300/CBP (CREB-binding protein) and is 
therefore also imperative for proper transcriptional activity [249].  
The STAT proteins are predominantly found as latent, unphosphorylated 
monomers within the cytoplasm, although some work has shown that they can 
also exist as preformed dimers and/or within larger protein complexes that may 
possibly act to facilitate STAT redistribution to activated receptors [250-254]. 
Interestingly, studies have indicated that instead of being entirely cytoplasmic, 
STAT3 might continuously shuttle back and forth from the nucleus to the 
cytoplasm [255, 256]. Several cytokines and their receptors, growth factors and 
their receptors, and non-receptor tyrosine kinases are known to activate the 
STAT proteins by tyrosine phosphorylation-induced dimerization. For example, it 
is well known that STAT3 can be activated by EGF binding to EGFR, platelet-
derived growth factor (PDGF) binding to the PDGF receptor (PDGFR), and Src 
[235, 257-260]. Canonical activation of STAT3 occurs via a Janus kinase (JAK) 
that is non-covalently bound to a cytokine receptor unit, such as glycoprotein-130 
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(gp130) [234]. Because cytokine receptors lack enzymatic activity, they rely on 
intracellular non-receptor kinases (i.e. JAKs) to propagate cytokine binding 
signals. Several cytokines, including IL-6, IL-10, leukemia inhibitory factor (LIF), 
and oncostatin M (OSM), can bind gp130 and induce either homodimerization 
with another gp130 receptor unit or heterodimerization with a different cytokine 
receptor unit, such as the IL-6 receptor [234, 236, 261-263]. Receptor 
dimerization initiates JAK transphosphorylation, and the now activated JAKs can 
then phosphorylate the receptor at up to six intracellular tyrosine residues. These 
phosphorylated tyrosines now act as docking sites for the STAT proteins via their 
SH2 domains. Docked STAT monomers are then phosphorylated by the JAKs on 
their highly conserved tyrosine residue leading to rapid dimerization of two STAT 
molecules via their phosphorylated-SH2 domains. All STAT proteins 
homodimerize, although STAT1:STAT2 and STAT1:STAT3 heterodimers have 
also been observed. In their now active dimer state, the STATs translocate to the 
nucleus, where they undergo facilitated transport into the nucleus. In the nucleus, 
STATs bind to both DNA and co-activators and mediate transcription of many 
target genes. STAT3 is known to target genes involved in basically all cellular 
processes, including proliferation, angiogenesis, apoptosis, inflammatory 
response, and migration, and dysregulation of STAT3 is associated with many 
types of cancer. 
 
  41 
1.7.B STAT3 in breast cancer and the normal mammary gland. 
Evidence from primary breast cancer samples and breast cancer cell lines 
indicates that STAT3 is constitutively activated in 50-60% of all breast cancers 
regardless of HR or HER2 status [264-270]. Data demonstrate that the primary 
mode of STAT3 activation in breast cancer occurs via IL-6 signaling through its 
gp130 receptor to activate JAKs in both autocrine and paracrine fashions [270-
272]. Interestingly, STAT3 activation appears to be dispensable for breast tumor 
initiation [273, 274]. However, STAT3 activation has been linked to increased 
proliferation of breast cancer cells, potentially through its concurrent upregulation 
of genes such as Cyclin D1 and c-myc [269, 271, 275, 276]. Strengthening these 
results, it has been shown that blocking STAT3 either directly or indirectly leads 
to attenuated breast cancer cell growth [266, 272, 277]. Furthermore, constitutive 
activation of STAT3 has been shown to enhance migration and metastasis of 
breast cancer cells, while inhibition of STAT3 leads to decreased anchorage-
independent growth and metastatic potential of mammary tumor cells both in 
vitro and in vivo [273-275, 278, 279]. These effects are most likely mediated via 
the STAT3-induced expression of multiple MMPs [269]. 
Because of its aberrant activation in cancer, the potential of pSTAT3 to be 
a prognostic factor of breast cancer has been investigated. 
Immunohistochemistry (IHC) analysis of pSTAT3 demonstrates that nuclear 
localization of pSTAT3 correlates with increased short- and long-term survival of 
both node-negative and node-positive primary breast cancers and can be used 
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as an independent prognostic marker of improved survival [265, 280]. However, it 
was alternatively found that pSTAT3 correlates with incomplete pathological 
response of patients to chemotherapy, indicating that STAT3 activation is 
inversely correlated with chemosensitivity [264]. In fact, many studies have 
demonstrated that STAT3 activation confers breast cancer cell survival by 
directly activating Survivin (a member of the Inhibitor of Apoptosis family of 
proteins) and several anti-apoptotic members of the B cell CLL/lymphoma-2 
(BCL-2) family, including BCL-2, myeloid cell leukemia 1 (MCL-1), and BCL-2-
related gene, long isoform (BCL-xL) [264, 269, 275, 281, 282]. Moreover, STAT3 
activation correlates with expression of these molecules in invasive breast 
cancers and in patients that do not respond well to chemotherapy, suggesting 
that STAT3 activation is a common occurrence in chemoresistance [264, 269]. 
Indeed, several studies have demonstrated that either direct or indirect inhibition 
of STAT3 restores or increases chemoresponsiveness of breast cancer cells and 
increases breast cancer cell apoptosis [277, 279, 281-284]. 
It is interesting that STAT3 activation inhibits apoptosis of breast cancer 
cells because STAT3 in the normal mammary gland is required to initiate 
apoptosis of epithelial cells. Following weaning, STAT3 activation is increased 
dramatically and is imperative for the subsequent process of involution that 
occurs when milk production is no longer necessary. Cre-mediated Stat3 removal 
in the mammary gland via β-lactoglobulin Cre results in a severe delay of 
involution and a decrease in apoptosis [34, 285]. It is thought that this STAT3-
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induced involution of the mammary gland proceeds initially through LIF and is 
sustained via STAT3-mediated autocrine OSM signaling [262, 263]. Interestingly, 
even though STAT3 is a known activator of the anti-apoptotic protein, BCL-xL, 
removal of STAT3 in the mammary gland does not appear to greatly alter the 
levels of BCL-xL [34, 269, 285]. Instead, there is decrease in insulin-like growth 
factor-binding protein-5 (IGFBP-5), which acts to inhibit survival signaling through 
IGF-1 by sequestering IGF-1 during involution, in STAT3 depleted mammary 
glands [34].  
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1.8 Thesis Goal 
The results of the studies from published literature described thus far 
demonstrate how the controlled regulation of several factors is essential for 
proper mammary gland formation and how the dysregulation of even just one 
factor can easily elicit a chain reaction of dysregulation that consequentially 
results in breast cancer. It is the goal of my research to gain a better 
understanding of how amplification of FGFR1 ultimately mediates breast cancer 
progression. As there are no currently available inhibitors that are specific for 
FGFR1, identification and examination of FGFR1-induced genes and how these 
molecules all interact could direct us to novel or more effective targets for 
therapies. This area of investigation is fundamental because of the clear need for 
more targeted therapies, especially for patients with TNBCs. 
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Chapter 2: Fibroblast growth factor receptor-1 
induced mammary tumorigenesis requires 
activation of the epidermal growth factor receptor 
 
2.1 Introduction 
The fibroblast growth factor receptor (FGFR) family consists of four 
receptor tyrosine kinases that are known regulators of cellular processes such as 
proliferation, migration, survival, and angiogenesis [91, 96, 286, 287]. Anomalous 
expression or uncontrolled activation of these receptors or their ligands has been 
correlated with progression of various types of cancer, including breast cancer 
[113, 288, 289]. Specifically, the chromosomal locus of FGFR1, 8p11-12, is 
found to be aberrantly amplified in approximately 10% of patients diagnosed with 
breast cancer [116, 119, 290, 291]. Patients who harbor the FGFR1 amplification 
do not respond well to current therapies and develop resistance to hormone-
based therapies [120, 121]. Therefore, understanding the molecular mechanisms 
of how FGFR1 overexpression promotes tumorigenesis may provide insights into 
better targets for novel, more effective therapies. 
Because of the lack of binding specificity amongst the FGF ligands and 
their receptors, it is difficult to specifically activate FGFR1. Therefore, an 
inducible FGFR1 (iFGFR1) system was previously engineered to mimic 
endogenous FGFR1 signaling [127]. Because the extracellular ligand-binding 
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domain was removed, dimerization and activation of iFGFR1 is stimulated not by 
FGF ligands but by the synthetic molecule AP20187 (AP). Binding of AP to 
iFGFR1 results in homodimerization and subsequent activation of the same 
signaling pathways as endogenous FGFR1. Extensive characterization of the 
iFGFR1 system in vitro found that, following AP treatment of mouse mammary 
epithelial cells expressing iFGFR1, there was an increase in cellular migration, 
proliferation, and signaling through the extracellular signal-regulated kinase 1/2 
(ERK1/2) pathway, similar to endogenous FGFR1 activation [127, 128, 292]. The 
inducible system was also analyzed in vivo. For these studies, a transgenic 
mouse line was created in which the iFGFR1 construct was placed under the 
control of the mouse mammary tumor virus (MMTV) promoter, thereby restricting 
iFGFR1 expression to mammary epithelial cells [127]. MMTV-iFGFR1 transgenic 
animals developed neoplasias within as little as three days of AP treatment, 
which were characterized by aberrant budding of the mammary gland ductal 
epithelial cells due to increased cellular proliferation. Extended AP treatment led 
to progressively more severe phenotypes, and by four weeks of iFGFR1 
activation, the mammary glands of transgenic animals contained large, locally 
invasive growths. These results verify that iFGFR1 activation promotes 
tumorigenic phenotypes both in vivo and in vitro. To identify mechanisms by 
which FGFR1 promotes tumorigenesis, previously published studies have 
described the results of microarray studies that were performed on mammary 
glands from MMTV-iFGFR1 transgenic mice following iFGFR1 activation [129]. In 
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the current study, we explore the ability of two targets identified in the screen, 
amphiregulin (AREG) and epiregulin (EREG), to promote FGFR1-induced 
mammary tumorigenesis.  
AREG and EREG are both members of the epidermal growth factor (EGF) 
family of ligands [reviewed in 293]. These ligands are originally synthesized as 
transmembrane proteins and are thought to be cleaved from the plasma 
membrane by a disintegrin and metalloproteinase (ADAM) sheddases [107, 132, 
136, 162, 164, 183, 185]. Furthermore, both ligands are known activators of the 
EGF receptor (EGFR); AREG exclusively binds to and signals through EGFR 
[131], whereas EREG can also bind to and signal through ErbB4 [186, 187]. 
AREG is critical for normal ductal morphogenesis in the mammary gland [20, 
154] and has also been linked to breast cancer progression [174, 176, 294, 295]. 
Studies examining AREG expression in human breast cancers have found AREG 
expression to significantly correlate with regional lymph node metastases, large 
tumor size, and high-grade tumors [169, 180, 296]. While EREG promotes 
proliferation of several normal and cancerous cell types [188, 190, 192, 193], the 
role of EREG has not been extensively characterized in the mammary gland. 
However, recent studies have demonstrated that EREG is a potent mediator of 
metastasis of breast cancer cells to the lung and that overexpression of EREG is 
an indicator of poor prognosis for inflammatory breast cancer patients [197-199].  
EGFR, a member of the ErbB receptor tyrosine kinase family, has been 
well studied in numerous systems [203, 297]. In the mammary gland, it is known 
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that EGFR is required for normal mammary gland ductal morphogenesis [167, 
298]. However, overexpression or constitutive activation of EGFR in the 
mammary gland has been linked to mammary tumorigenesis [214, 299, 300]. 
Additionally, overexpression of EGFR in the breast is associated with recurrence 
of earlier stage breast cancers and decreased disease-free and overall survival 
in later stage breast cancer patients [301-305]. Therefore, together with the fact 
that iFGFR1 activation in the mouse mammary gland of MMTV-iFGFR1 
transgenic animals leads to upregulation of the EGFR ligands AREG and EREG, 
these data strongly support a model in which aberrant FGFR1 signaling requires 
EGFR activation for mammary tumor formation, a link that has not been 
previously established. Moreover, the EGFR kinase inhibitor erlotinib is currently 
an approved therapeutic for both non-small cell lung cancer (NSCLC) patients 
and advanced pancreatic cancer patients [reviewed in: 306, 307]. However, 
erlotinib has not been fully tested as a functional therapy for breast cancer 
patients. 
Our current studies focus on identifying downstream mediators of iFGFR1-
induced mammary tumorigenesis. We have found that treatment of HC11 mouse 
mammary epithelial cells with either AREG or EREG promotes increased 
migration, proliferation, and ERK1/2 activation in vitro. Importantly, the ability of 
these ligands to stimulate migration and proliferation in vitro requires activation of 
EGFR, as inhibiting the EGFR kinase blocks these processes. We also show that 
inhibiting EGFR in vivo blocks iFGFR1-mediated cellular proliferation of mouse 
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mammary epithelial cells. These studies demonstrate that activation of EGFR is 
important for effective FGFR1-induced mammary tumorigenesis. Because there 
are currently no FGFR1-specific drugs that are used clinically, our studies 
suggest that inhibition of EGFR might represent a useful strategy for targeting 
breast cancers harboring FGFR1 amplifications.  
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2.2 Materials and Methods 
2.2.A Cell culture and treatment. 
Generation of HC11 cells stably expressing the iFGFR1 construct 
(HC11/R1 cells) was described previously [128], and the cells were obtained 
from Dr. Jeff Rosen (Baylor College of Medicine, Houston, TX, USA). Cells were 
maintained in HC11/R1 complete media [serum free (SF)-RPMI (Invitrogen, 
Carlsbad, CA, USA) supplemented with final percentages/concentrations of 10% 
FBS (Invitrogen), 1% Pen Strep (Invitrogen), 5 μg/mL Insulin (Sigma-Aldrich 
Corporation, St. Louis, MO, USA), 10 ng/mL EGF (Invitrogen), and 0.7 μg/mL 
Puromycin (Sigma-Aldrich Corporation)]. HC11 cells were maintained in HC11 
complete media (HC11/R1 complete media without Puromycin). Prior to 
treatment with 30 nM AP (Ariad Pharmaceuticals, Cambridge, MA, USA) or its 
ethanol solvent, confluent cells were rinsed twice with 1xPBS (Cellgro, 
Manassas, VA, USA) and incubated in SF-RPMI overnight. Two μM erlotinib 
(Boynton Pharmacy, University of Minnesota, Minneapolis, MN, USA), 1 μM 
erlotinib, 0.5 μM erlotinib, or DMSO (Sigma-Aldrich Corporation) as a solvent 
control, was added to the SF media as indicated. MCF7 cells were previously 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, 
USA) and maintained in MCF7 complete media [SF-DMEM (Invitrogen) 
supplemented with final percentages/concentrations of 10% FBS, 1% Pen Strep, 
and 5 μg/mL Insulin]. Prior to treatment with basic (b)FGF (Invitrogen), confluent 
MCF7 cells were rinsed twice with 1xPBS and starved overnight in SF-DMEM. 
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For bFGF treatment, cells were incubated for the indicated times in bFGF diluted 
in SF media to 50 ng/mL. All cells were grown and maintained at 37°C in 5% 
CO2. 
 
2.2.B RNA isolation and qRT-PCR analysis. 
RNA was isolated from HC11/R1 and MCF7 cells and from the fourth 
inguinal mammary glands of MMTV-iFGFR1 transgenic mice using TRIzol® 
(Invitrogen) as described previously [129, 308]. For quantitative reverse 
transcription-PCR (qRT-PCR) analysis, cDNA was generated using the 
Quantitect Reverse Transcription kit (Qiagen, Valencia, CA, USA). Between one-
tenth and one-sixteenth of the final reaction volume was used in quantitative 
SYBR green RT-PCR reactions as described previously [309] using the Bio-Rad 
iQ5 system (Bio-Rad, Hercules, CA, USA). Relative quantification of the 
expression of each gene was calculated and normalized to averaged cyclophilin 
B expression levels using the 2-Ct method [310]. The following mouse primer 
sequences were used: Areg: 5’-GGGGACTACGACTACTCAGAG-3’ and 5’-
TCTTGGGCTTAATCACCTGTTC-3’, Ereg: 5’-TCCGAGGATAACTGTACCGC-3’ 
and 5’-CTCTCATGTCCACCAGGTAGAT-3’, and cyclophilin B: 5’-
TGAGCACTGGGGAGAAAGG-3’ and 5’-TTGCCATCCAGCCACTCAG-3’. For 
experiments with MCF7 cells, the following human primers were used: AREG: 5’-
GTGGTGCTGTCGCTCTTGATA-3’ and 5’-ACTCACAGGGGAAATCTCACT-3’, 
EREG: 5’-CTGCCTGGGTTTCCATCTTCT-3’ and 5’-
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GCCATTCATGTCAGAGCTACACT-3’, and cyclophilin B: 5’-
GAAAGAGCATCTACGGTGAGC-3’ and 5’-GTCTTGACTGTCGTGATGAAGAA-
3’. Experiments were performed in biological triplicates. Statistical analysis was 
performed using the unpaired student’s t-test to compare two means (GraphPad 
QuickCalcs, GraphPad Software, Inc., CA, USA). 
 
2.2.C Immunohistochemistry. 
The following antibodies were used for immunohistochemistry (IHC): anti-
AREG (AF989) and anti-EREG (AF1068) (R&D Systems, Minneapolis, MN, 
USA). For both antibodies, sodium citrate antigen retrieval was used as 
described previously [311] and primary antibodies were used at a concentration 
of 15 μg/mL. IHC analysis was performed on mammary gland sections from a 
minimum of three mice per treatment and genotype. 
 
2.2.D ELISAs. 
HC11/R1 cells were plated in six well plates in complete media, grown to 
confluence, serum starved, and then treated with either 30 nM AP or its ethanol 
solvent overnight. MCF7 cells were also plated in six well plates in complete 
media, grown to confluence, serum starved, and then treated with 50 ng/mL 
bFGF for 4, 6, or 24 hours. Conditioned media were collected and used to 
quantify soluble ligand concentration of AREG and/or EREG using ELISA kits 
(R&D Systems) and performed according to the company’s protocol. 
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Experiments were performed in biological triplicates. Statistical analysis was 
performed using the unpaired student’s t-test to compare two means (GraphPad 
QuickCalcs). 
 
2.2.E Migration assays. 
For AREG and EREG overexpression, HC11 cells were plated in six well 
plates in complete media, grown to confluence, and then starved in SF-RPMI. 
The next day, a p10 pipette tip was used to make a scratch down the center of 
each well. Cells were then treated with either 20 ng/mL recombinant mouse 
(rm)AREG (R&D Systems) or 10 ng/mL rmEREG (R&D Systems) in the 
presence or absence of either 1 μM or 0.5 μM erlotinib or an equivalent amount 
of DMSO. To test iFGFR1-induced migration, HC11/R1 cells were plated in six 
well plates in complete media, grown to confluence, and then starved in SF-
RPMI overnight. Serum starved cells were treated with 30 nM AP or an 
equivalent amount of ethanol overnight. Additionally, the HC11/R1 cells were 
treated with 1 μM erlotinib or an equivalent amount of DMSO. All treatments were 
done in biological triplicates. Five representative pictures of each scratch were 
taken at the original time of treatment and 18 hours later. Areas of the open 
space in each picture were determined using the Leica LAS software, and 
percent wound closure was calculated for each treatment. Statistical analysis 
was performed using the unpaired student’s t-test to compare two means 
(GraphPad QuickCalcs).  
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2.2.F MTT assays.   
HC11 or HC11/R1 cells were plated on day 0 in complete medium into 24 
well tissue culture plates at 20,000 cells/well. Cells were grown overnight and 
then starved in SF-RPMI. The next day, cells were activated with 100 ng/mL 
rmAREG (HC11 cells), 10 ng/mL rmEREG (HC11 cells), or 30 nM AP (HC11/R1 
cells) in the presence or absence of 1 μM erlotinib or an equivalent amount of 
DMSO. After 48 (HC11 cells) or 72 (HC11/R1 cells) hours, Thiazolyl Blue 
Tetrazolium Bromide (Sigma-Aldrich Corporation) was added to each well at a 
final concentration of 0.3 mg/mL for 2 hours. Medium was then removed from 
wells, and the cells were solubilized in 95%DMSO/5%1xPBS. Solubilized dye 
was detected on a plate reader at an OD of 570 nm with background 
fluorescence at 650 nm subtracted from each value. Experiments were 
performed in biological triplicates. Statistical analysis was performed using the 
unpaired student’s t-test to compare two means (GraphPad QuickCalcs). 
 
2.2.G Immunoblot analysis. 
HC11 or HC11/R1 cells were plated in six well plates in complete media, 
grown to confluence, and then starved in SF-RPMI overnight. The next day, each 
well of HC11 cells was treated with 20 ng/mL rmAREG or 10 ng/mL rmEREG for 
the indicated time (Fig. 3E) to overnight (Fig. 3F) in the presence or absence of 
either 1 μM or 0.5 μM erlotinib or an equivalent amount of DMSO. HC11/R1 cells 
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were treated with either 30 nM AP or ethanol in the presence of either 1 μM 
erlotinib or an equivalent amount of DMSO for 7 or 18 hours (Fig. 4A and 4E). 
Alternatively, HC11/R1 cells were treated with 30 nM AP with 2 μM erlotinib or an 
equivalent amount of DMSO for the times indicated (Fig. 4D). Following all 
treatments, lysates were collected in RIPA buffer, and total protein concentration 
was determined using a Bradford assay. Thirty μg protein was analyzed on an 
SDS-PAGE gel, and immunoblotting for phosphorylated (p)Akt (1:2000, 9271, 
Cell Signaling, Danvers, MA, USA), Cyclin D1 (1:2000, 2926, Cell Signaling), β-
tubulin (1:1000, 2146, Cell Signaling), EGFR (1:100,000, ab52894, Abcam, 
Cambridge, MA, USA), pEGFR at Y845 (1:1000, 2231, Cell Signaling), pEGFR at 
Y1068 (1:1000, 3777, Cell Signaling), pEGFR at Y1173 (1:1000, ab5652, 
Abcam), or pERK1/2 (1:500, 9101, Cell Signaling) was performed. Additionally, 5 
μg protein was analyzed on an SDS-PAGE gel, and immunoblotting for total Akt 
(1:1000, 9272, Cell Signaling) or ERK1/2 (1:2000, sc-94, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was performed. Experiments were 
performed at least three separate times. 
 
2.2.H Animals.  
Generation of MMTV-iFGFR1 transgenic mice has been described 
previously [127] and the mice were obtained from Dr. Jeff Rosen. Animal care 
and procedures were approved by the Institutional Animal Care and Use 
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Committee of the University of Minnesota and were in accordance with the 
procedures detailed in the Guide for Care and Use of Laboratory Animals. 
 
2.2.I Treatment of mice. 
For the first study, six week old MMTV-iFGFR1 female mice were 
administered 25 mg/kg/day erlotinib or an equivalent amount of the DMSO 
solvent via oral gavage once daily for 3 days. On the second day of oral gavage 
treatment, the mice were also given intraperitoneal (i.p.) injections of 1 mg/kg AP 
to activate iFGFR1. Twenty-four hours after the third oral gavage, the mice were 
given i.p. injections of 0.3 mg/kg BrdU (GE Healthcare Life Sciences, 
Piscataway, NJ, USA). For the second study, six week old MMTV-iFGFR1 
female mice were given i.p. injections of 1 mg/kg/day AP to activate iFGFR1 on 
days 1, 5, and 9. The mice were then treated with 25 mg/kg/day erlotinib or an 
equivalent amount of the DMSO solvent via oral gavage once daily for five 
consecutive days (days 10-14). On day 15, mice were given i.p. injections of 0.3 
mg/kg BrdU. All mice were sacrificed 2 hours post-BrdU injections, and their 
fourth inguinal mammary glands were harvested for further analysis.  
 
2.2.J Mammary gland histology and measurement of epithelial budding. 
Glands were fixed in fresh 4% PFA for 2 hours on ice and then stored in 
70% ethanol. Whole mounts were prepared as previously described [129]. For 
histological and immunofluorescence (IF) analysis, glands were embedded in 
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paraffin and sectioned at 5 μm. To calculate percent budding structures, 5 μm 
sections were stained with hematoxylin and eosin (H&E) according to standard 
protocols. Each epithelial structure distal to the lymph node was counted and 
grouped into either no budding, moderate budding (1-4 buds), or severe budding 
(>4 buds). Percent budding structures was calculated by comparing all budding 
structures to all structures for each category of mice. At least three sections were 
analyzed per mouse. For IF analysis, 5 μm sections were stained with anti-BrdU 
(1:300, ab6326, Abcam, Cambridge, MA, USA) according to standard IF 
protocols. Sections were mounted in ProLong® Gold antifade reagent with DAPI 
(Invitrogen) to visualize the nuclei. Ten epithelial ductal structures distal to the 
lymph node were imaged per mammary gland section. Based on DAPI staining, 
all epithelial cells within each structure were counted and all BrdU positive 
epithelial cells of the same structure were counted to determine percent BrdU 
positive cells. A minimum of 1500 epithelial cells were counted per treatment 
group, and all studies were performed in a blinded manner. Statistical analysis 
was performed using the unpaired student’s t-test to compare two means 
(GraphPad QuickCalcs).  
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2.3 Results 
2.3.A Activation of iFGFR1 in the mouse mammary gland results in 
increased expression of AREG and EREG.  
Due to the prevalence of human breast cancer patients harboring aberrant 
FGFR1 amplification, it is necessary to determine the downstream molecular 
effects of FGFR1-induced signaling pathways. In order to specifically study 
FGFR1 signaling, an inducible FGFR1 system previously engineered to mimic 
endogenous FGFR1 signaling was developed [127]. Activation of iFGFR1, by 
treatment with AP, within the mammary epithelial cells of MMTV-iFGFR1 
transgenic mice results in the formation of hyperplastic lesions within 3 days, 
which progress to mammary tumors upon prolonged AP treatment. To identify 
novel mediators of such FGFR1-induced tumorigenesis, previously published 
studies described the results of microarray studies that were performed on RNA 
isolated from the mammary glands of MMTV-iFGFR1 transgenic animals 
following a AP stimulation [129]. Of the numerous genes induced by iFGFR1, two 
EGF family ligands, Areg and Ereg, were significantly upregulated following 
iFGFR1 activation (Fig. 1A and 1B). Areg was significantly induced within 8 hours 
of treatment, while Ereg was significantly induced following 16 hours of 
treatment. To validate increased expression of Areg and Ereg, IHC analysis of 
MMTV-iFGFR1 mammary gland sections was performed. As shown in Figure 1C, 
both AREG and EREG proteins were produced at elevated levels following 
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Figure 1: AREG and EREG are induced following FGFR1 activation in vivo. 
A and B) MMTV-iFGFR1 animals were administered i.p. injections of 1 mg/kg AP for the 
times indicated. Following AP treatment, the animals were sacrificed, and their fourth 
inguinal mammary glands were removed for either isolation of RNA or paraffin embedding 
and subsequent tissue analysis. RNA samples were subjected to microarray analysis in 
previously published studies [129]. Analysis of the data from these experiments 
demonstrated that Areg (A) and Ereg (B) were both significantly upregulated at the indicated 
timepoints. Error bars represent s.e.m. (*P<0.05) C) Paraffin-embedded mammary glands 
from either wildtype (WT) or MMTV-iFGFR1 mice treated with AP for 48 hours were 
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sectioned. IHC was performed on sections to detect either AREG or EREG. Images are 
representative of at least three mice per treatment group. Scale bars = 50 μm. 
  61 
iFGFR1 activation. These studies identify two novel targets of FGFR1 activation 
in the mammary gland in vivo. 
 
2.3.B Activation of iFGFR1 in HC11/R1 cells induces expression of AREG 
and EREG.  
We next determined whether iFGFR1 was capable of inducing AREG and 
EREG in mouse mammary epithelial cells. For these studies, HC11/R1 cells, an 
immortalized, non-transformed mammary epithelial cell line stably expressing 
iFGFR1, were used. Previous studies of HC11/R1 cells have demonstrated that 
activation of iFGFR1 via treatment with AP promotes cell survival, proliferation, 
migration, invasion, and epithelial-to-mesenchymal transition (EMT) [127, 128, 
292, 312]. qRT-PCR was performed on RNA collected from HC11/R1 cells 
treated with AP for 0, 0.5, 1, 2, and 4 hours. As shown in Figures 2A and 2B, 
both Areg and Ereg transcript levels significantly increased following iFGFR1 
activation in vitro. Areg transcript levels rapidly increased with AP treatment, 
peaking at 1 hour of AP treatment, and then decreased with prolonged AP 
treatment. Ereg transcript levels rose more slowly to peak at 2 hours post-AP 
treatment and then, like Areg, decreased with continued AP treatment. These 
data are consistent with the in vivo analysis of Areg and Ereg transcripts in that 
an increase in Areg mRNA is detectable earlier than an increase in Ereg mRNA 
and demonstrate that Areg and Ereg are induced in mouse mammary epithelial 
cells following iFGFR1 activation. 
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To verify that Areg and Ereg transcripts are indeed translated into mature 
AREG and EREG proteins in vitro, AREG and EREG protein levels were 
quantified. Because it is known that EGF family ligands are shed from their 
membrane-bound precursors into the extracellular matrix (ECM) [162, 164], 
soluble AREG and EREG protein concentration was measured by ELISA from 
the conditioned media of HC11/R1 cells treated overnight with either AP or its 
solvent, ethanol. Compared to the ethanol controls, HC11/R1 cells treated with 
AP had significantly increased levels of soluble AREG and EREG (Fig. 2C and 
2D). These data suggest that iFGFR1 activation induces both gene and protein 
expression of AREG and EREG.  
 
2.3.C AREG and EREG expression are upregulated following bFGF 
treatment in MCF7 cells. 
Further studies were performed to confirm that AREG and EREG are 
regulated by FGF signaling in a breast cancer model. The MCF7 human breast 
cancer cell line has been previously used to study mechanisms of FGF-induced 
tumorigenesis [313, 314] and was used to verify that FGF treatment leads to 
increased expression of AREG and EREG. As shown in Figure 2, qRT-PCR 
performed on RNA isolated from MCF7 cells treated with 50 ng/mL bFGF for 4, 
6, and 24 hours displayed a significantly increased fold change in both AREG 
and EREG mRNA as compared to the no treatment control samples (Fig. 2F and 
2G). As in the mouse, human AREG and EREG are shed from the cell 
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membrane. Thus, conditioned media were collected to detect AREG protein 
levels via ELISA (Fig. 2E). Compared to the no treatment control, 50 ng/mL 
bFGF treatment of MCF7 cells for 4, 6, and 24 hours significantly induced soluble 
human AREG protein. These results demonstrate that activation of the 
endogenous FGF pathway by treating cells with ligand also increases AREG and 
EREG expression. Furthermore, as MCF7 cells are a human-derived breast 
cancer cell line, these studies suggest that activation of the FGF pathway signals 
an increase in both AREG and EREG expression in human cells as well as 
mouse cells. 
 
2.3.D. AREG and EREG both individually promote cellular migration and 
proliferation of mammary epithelial cells in vitro.  
Based on the fact that both AREG and EREG are upregulated following 
iFGFR1 activation and that iFGFR1 activation induces numerous tumorigenic 
phenotypes including migration and proliferation, we tested whether AREG 
and/or EREG affects these processes. To study the effects of AREG and EREG 
on migration, rmAREG or rmEREG was added to freshly wounded serum starved 
HC11 mouse mammary epithelial cells, which do not express iFGFR1. Percent 
wound closure was calculated from the original time 0 to 18 hours post-
recombinant protein treatment. Compared to controls treated only with DMSO, 
addition of either rmAREG or rmEREG significantly increased HC11 migration  
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Figure 2: FGFR1 activation in mammary epithelial cells in vitro induces expression of 
AREG and EREG. 
A and B) Mouse mammary epithelial HC11/R1 cells were treated with 30 nM AP for the 
indicated times. Following AP treatment, qRT-PCR analysis was performed on RNA isolated 
at each timepoint for both Areg transcript (A) and Ereg transcript (B) and normalized to 
mouse cyclophilin B. Experiments were performed in biological triplicates. Error bars 
represent s.e.m. (*P<0.05, **P<0.01, ***P<0.005, ****P<0.001) C and D) To detect soluble 
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AREG (C) and EREG (D) ligands, ELISA analysis was performed on conditioned HC11/R1 
media. HC11/R1 cells were treated with either 30 nM AP or its ethanol solvent overnight to 
condition the media. Experiments were performed in biological triplicates. Error bars 
represent s.e.m. (*P<0.05) E) The conditioned media of MCF7 human breast cancer cells 
treated with 50 ng/mL bFGF for 4, 6, or 24 hours were collected and soluble AREG was 
detected via ELISA. Experiments were performed in biological triplicates. Error bars 
represent s.e.m. (*P<0.05, ****P<0.001) F and G) MCF7 cells were treated with 50 ng/mL 
bFGF for 4, 6, or 24 hours. Following bFGF treatment, qRT-PCR analysis was performed on 
RNA isolated at each timepoint for both AREG transcript (F) and EREG transcript (G) and 
normalized to human cyclophilin B. NT=no treatment. Experiments were performed in 
biological triplicates. Error bars represent s.e.m. (****P<0.001)  
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(Fig. 3A and 3B). Because AREG and EREG both activate EGFR [131, 186, 
187], we examined the effects of blocking signaling through EGFR on the 
migratory potential of the rmAREG- or rmEREG-treated cells. For these studies, 
we used the EGFR inhibitor erlotinib, which exerts its effects by blocking EGFR 
kinase function. Cells treated with either rmAREG or rmEREG and erlotinib had 
significantly decreased migration compared to the rmAREG- or rmEREG-treated 
cells, similar to the DMSO-treated control levels (Fig. 3A and 3B). Moreover, 
erlotinib alone did not affect the migration of the HC11 cells as compared to the 
DMSO-treated controls (Fig. 3A and 3B), suggesting that the reduction in 
migration is not due to erlotinib-induced off-target effects but is due to an 
inhibition of EGFR signaling. These data suggest that treatment of cells with 
AREG or EREG alone is enough to promote increased mammary epithelial cell 
migration, a hallmark of tumor progression. Furthermore, this migration is 
promoted at least in part through EGFR, as blocking EGFR activity by addition of 
erlotinib significantly impairs the ability of these epithelial cells to migrate into the 
open space of the wound. 
Previous studies have also demonstrated that activation of iFGFR1 
induces proliferation of mammary epithelial cells [127, 128, 292]. Because EGFR 
activation has also been linked to increased proliferation, we hypothesized that 
the upregulation of EGF ligands, such as AREG and EREG, might promote 
proliferation. Therefore, initial studies were performed to determine the ability of 
AREG and EREG to stimulate mammary epithelial cell proliferation. For these 
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studies, HC11 cells were treated with rmAREG or rmEREG and either DMSO or 
erlotinib for 48 hours prior to performing an MTT assay. Treatment of HC11 cells 
with either rmAREG (Fig. 3C) or rmEREG (Fig. 3D) significantly promoted 
proliferation compared to DMSO-treated controls and this proliferation was 
significantly blocked with erlotinib treatment. Taken together, these data 
demonstrate that treatment of mammary epithelial cells with recombinant AREG 
or EREG promotes EGFR-dependent migration and stimulates EGFR-dependent 
mammary epithelial cell proliferation.  
 
2.3.E AREG and EREG stimulate ERK activation in vitro, which is inhibited 
by erlotinib. 
The results described above, in which AREG and EREG treatment 
stimulates migration and proliferation of HC11 mammary epithelial cells that is 
blocked by addition of the EGFR kinase inhibitor erlotinib, suggest that EGFR 
activation is required for AREG and EREG to exert their signaling effects. 
Because a known target of EGFR activation is ERK1/2, we next examined the 
activation profile of ERK1/2 following rmAREG or rmEREG treatment. HC11 cells 
were treated with either rmAREG or rmEREG for various times up to 1 hour and 
immunoblot analysis was performed to examine pERK1/2 and total ERK1/2. Both 
rmAREG and rmEREG treatments led to increased ERK1/2 activation by 5 
minutes that was largely diminished within 15 minutes (Fig. 3E). These results 
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suggest that AREG or EREG treatment induces rapid and transient ERK1/2 
activation. 
To confirm that the detected pERK1/2 is regulated by EGFR, HC11 cells 
were treated with rmAREG or rmEREG in the presence or absence of erlotinib 
for 10 minutes. Compared to DMSO-treated controls, rmAREG- or rmEREG-only 
treated cells showed increased phosphorylation of ERK1/2 (Fig. 3F), as expected 
based on our above results. Notably, treatment of cells with erlotinib at either 1 
μM or 0.5 μM, in addition to rmAREG or rmEREG, blocked ERK1/2 
phosphorylation (Fig. 3F), suggesting that blocking EGFR activation, and thus 
signaling through EGFR, blocks activation of ERK1/2 in mammary epithelial cells. 
These data imply that EGFR must be activated in order for AREG and EREG to 
exert their effects and that blocking EGFR signaling effectively inhibits the effects 
of AREG and EREG stimulation. 
 
2.3.F Activation of iFGFR1 in mammary epithelial cells induces migration, 
proliferation, and ERK1/2 activation in vitro, which are inhibited by 
erlotinib.  
As shown thus far, iFGFR1 activation upregulates expression of the EGFR 
ligands AREG and EREG and the EGFR-specific inhibitor erlotinib blocks AREG- 
and EREG-induced cellular processes and signaling. Therefore, we next 
assessed whether EGFR is activated following iFGFR1 activation in HC11/R1 
cells. Serum-starved HC11/R1 cells were treated with AP or ethanol for 18 hours  
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Figure 3: Treatment of HC11 cells with either AREG or EREG in vitro stimulates 
cellular migration, cellular proliferation, and ERK activation. 
A) Freshly wounded mouse mammary epithelial HC11 cells were treated with either DMSO, 
20 ng/mL rmAREG+DMSO, 1 μM erlotinib, 20 ng/mL rmAREG+1 μM erlotinib, 0.5 μM 
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erlotinib, or 20 ng/mL rmAREG+0.5 μM erlotinib for 18 hours. Five representative images 
were taken per well at 0 and 18 hours, and the area of the open space of the wound was 
determined using Leica LAS Software. Migration was measured as percent wound closure. 
Each treatment was performed in biological triplicates. Error bars represent s.e.m. 
(****P<0.001) B) Migration assay was performed as in (A), with the exception that HC11 cells 
were treated with 10 ng/mL rmEREG instead of rmAREG. Each treatment was performed in 
biological triplicates. Error bars represent s.e.m. (****P<0.001) C) HC11 cells were treated 
with DMSO, 100 ng/mL rmAREG, 1 μM erlotinib, or 100 ng/mL rmAREG+1 μM erlotinib for 
48 hours. Proliferation was measured via MTT assay and normalized to the levels at 
treatment day 0. Each treatment was performed in biological triplicates. Error bars represent 
s.e.m. (**P<0.01, ***P<0.005) D) HC11 cells were treated as in (C), but with 10 ng/mL 
rmEREG in place of rmAREG. Proliferation was measured via MTT assay at 48 hours and 
normalized to the levels at day 0 of treatment. Each treatment was performed in biological 
triplicates. Error bars represent s.e.m. (***P<0.005) E) HC11 cells were treated with either 20 
ng/mL rmAREG or 10 ng/mL rmEREG for the indicated times. Following treatment, whole 
cell lysates were collected and analyzed by immunoblot for pERK1/2 and total ERK1/2. 
Experiment shown is representative of three individual experiments. F) HC11 cells were 
treated with combinations of 20 ng/mL rmAREG or 10 ng/mL rmEREG and DMSO, 1 μM 
erlotinib, or 0.5 μM erlotinib as designated for 10 minutes. Whole cell lysates were collected 
and analyzed by immunoblot for pERK1/2 and total ERK1/2. Experiment shown is 
representative of three individual experiments. 
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before the phosphorylation status of three critical tyrosine residues within the 
EGFR kinase domain was evaluated. As shown in Figure 4A, AP treatment 
stimulated phosphorylation of residues Y845, Y1068, and Y1173 as compared to 
ethanol treatment, suggesting that activation of iFGFR1 does subsequently 
signal EGFR activation. 
Because treatment of cells with recombinant AREG and EREG protein 
stimulates migration and proliferation of HC11 cells, and because activating 
iFGFR1 results in EGFR phosphorylation, we next tested whether iFGFR1-
induced cellular processes were dependent upon EGFR activity. Freshly 
wounded serum-starved HC11/R1 cells were treated overnight with either AP 
and DMSO or ethanol and DMSO. Percent wound closure was calculated from 
the original time of treatment to 18 hours post-treatment. As expected based on 
previous studies [128], AP and DMSO treatment significantly stimulated 
migration of the HC11/R1 cells compared to ethanol and DMSO-treated controls 
(Fig. 4B). To determine whether EGFR activation is required for the increased 
iFGFR1-induced migration of HC11/R1 cells, we also added erlotinib to AP- or 
ethanol-treated cells. As shown in Figure 4B, addition of erlotinib to AP-treated 
cells partially, but significantly decreased migration to levels close to the ethanol 
and DMSO-treated control. Erlotinib treatment of the ethanol control cells did not 
inhibit migration as compared to the ethanol and DMSO-treated control cells, 
demonstrating that the decreased migration of the AP and erlotinib-treated 
HC11/R1 cells is not due to non-specific off-target effects of erlotinib. These 
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results suggest that iFGFR1 activation signals through EGFR to promote 
migration in vitro.  
To determine whether iFGFR1-mediated cellular proliferation could also 
be blocked by erlotinib treatment, an MTT assay was performed. As shown in 
Figure 4C, AP and DMSO treatment of HC11/R1 cells induced greater cellular 
proliferation than ethanol and DMSO-treated controls. This proliferation was 
partially, but significantly, inhibited by erlotinib treatment, suggesting that iFGFR1 
activation, at least in part, signals through EGFR to promote cellular proliferation 
in vitro. Moreover, erlotinib treatment of the ethanol control cells did not 
significantly block proliferation as compared to the ethanol and DMSO-treated 
control cells, again demonstrating that the reduction in proliferation of the AP and 
erlotinib-treated HC11/R1 cells is not due to off-target effects of erlotinib. 
To be certain that erlotinib does not inhibit iFGFR1-driven migration and 
proliferation by blocking iFGFR1 activity in a non-specific manner, HC11/R1 cells 
were treated with AP in the presence of erlotinib and phosphorylation of ERK1/2, 
a well-established downstream target of FGFR1 signaling, was determined. For 
these studies, serum-starved cells were treated for 0, 5, 10, 15, 30 and 60 
minutes with AP in the presence of either erlotinib or DMSO. As shown in Figure 
4D, erlotinib did not block iFGFR1-induced activation of ERK1/2 during this time-
course. These results demonstrate that erlotinib is not blocking migration and 
proliferation by non-specifically inhibiting iFGFR1 activity. 
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Based on these results, we predicted that the accumulation of AREG and 
EREG ligands over time leads to activation of EGFR and its downstream 
signaling pathways and that this autocrine stimulation of EGFR contributes to 
FGFR1-induced migration and proliferation. To address this prediction, 
immunoblot analysis of signaling molecules downstream of EGFR was performed 
on HC11/R1 cells treated with AP or ethanol in the presence or absence of 
erlotinib or DMSO for 7 or 18 hours. As expected, phosphorylation of Akt and 
ERK1/2 was higher in the 18 hour AP-treated samples as compared to ethanol-
treated samples (Fig. 4E). Moreover, cell cycle regulator Cyclin D1 expression 
was upregulated following 7 hours of AP treatment as compared to 7 hours of 
ethanol treatment. Importantly, erlotinib largely inhibited both Akt and ERK1/2 
phosphorylation and Cyclin D1 expression (Fig. 4E), suggesting that EGFR 
activation in HC11/R1 cells results in subsequent activation of several 
downstream signaling pathways.  
 
2.3.G Activation of iFGFR1 in vivo induces cellular proliferation of mouse 
mammary epithelial cells, which is inhibited by erlotinib.  
Activating iFGFR1 in vivo is known to stimulate aberrant epithelial cell 
budding due to increased proliferation of the epithelial cells [127]. Based on our 
above results in which AREG and EREG promote cellular proliferation in vitro in 
an erlotinib-dependent manner, we wanted to determine whether erlotinib could 
also inhibit aberrant cellular proliferation in vivo. For these studies, MMTV- 
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Figure 4: Erlotinib inhibits iFGFR1-induced migration, proliferation, and ERK1/2 
activation in vitro. 
A) HC11/R1 cells were treated with either ethanol or 30 nM AP for 18 hours. Whole cell 
lysates were collected and analyzed by immunoblot for total EGFR and EGFR 
phosphorylated at Y845, Y1068, and Y1173. Experiments shown are representative of three 
individual experiments. B) Freshly wounded mouse mammary epithelial HC11/R1 cells were 
treated with ethanol+DMSO, 30 nM AP+DMSO, ethanol+1 μM erlotinib, or 30 nM AP+1 μM 
erlotinib for 18 hours. Five representative images were taken per well at 0 and 18 hours, and 
the area of the open space of the wound was determined using Leica LAS Software. 
Migration was measured as percent wound closure. Each treatment was performed in 
biological triplicates. Error bars represent s.e.m. (***P<0.005, ****P<0.001) C) HC11/R1 cells 
were treated as in (B) for 72 hours. Proliferation was then measured via MTT assay and 
normalized to levels at day 0 of treatment. Each treatment was performed in biological 
triplicates. Error bars represent s.e.m. (*P<0.05, ****P<0.001) D) HC11/R1 cells were treated 
with 30 nM AP in the presence of either DMSO or 2 μM erlotinib for the times indicated. 
Whole cell lysates were collected and analyzed by immunoblot for pERK1/2 and total 
ERK1/2. Experiment shown is representative of three individual experiments. E) HC11/R1 
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cells were treated with either 30 nM AP or ethanol and either DMSO or 1 μM erlotinib for 7 
(Cyc D1 and β-tub) or 18 (Akt and ERK1/2) hours. Whole cell lysates were collected and 
analyzed by immunoblot for pAkt, total Akt, Cyc D1, β-tub, pERK1/2, and total ERK1/2. 
Experiments shown are representative of three individual experiments. 
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iFGFR1 transgenic mice were treated with erlotinib daily via oral gavage for 3 
days. To activate iFGFR1, the same mice were given intraperitoneal (i.p.) 
injections of AP on the second day of erlotinib treatment. Two days after iFGFR1 
activation, the mice were injected with BrdU 2 hours prior to sacrifice. The fourth 
inguinal mammary glands were harvested and either whole mounts or tissue 
sections were stained for further analysis. Using H&E staining, it was found that, 
compared to WT controls, mammary glands from mice in which iFGFR1 was 
activated exhibited more aberrant epithelial budding around the ductal lumens 
(Fig. 5A-D). This aberrant budding significantly decreased when the transgenic 
animals were treated with erlotinib in conjunction with iFGFR1 activation, 
suggesting that activation of EGFR is at least in part required for the anomalous 
mammary epithelial cell budding (Fig. 5A-D).  
The above described study indicates that preventive inhibition of EGFR 
might be a beneficial therapy; however, preventive treatment is not common in 
the clinic setting. Therefore, we performed a second in vivo study again using the 
MMTV-iFGFR1 transgenic mice. This time, iFGFR1 was activated with i.p. 
injections of AP on days 1, 5, and 9 prior to once daily treatment with erlotinib via 
oral gavage for 5 consecutive days (days 10-14). Mice were sacrificed on day 15 
2 hours after being injected with BrdU. Once again, the fourth inguinal mammary 
glands were harvested and whole mounts and tissue sections were analyzed. 
Mammary glands from iFGFR1-activated mice contained significantly more 
lateral epithelial budding as visualized using H&E staining than glands from WT  
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Figure 5: Erlotinib prevents FGFR1-induced mammary epithelial cell budding and 
proliferation in vivo. 
A to C) Representative images of H&E stained sections of paraffin-embedded mammary 
glands from WT (A), MMTV-iFGFR1 transgenic mice treated with 1 mg/kg AP via i.p. 
injections and either DMSO (B) or 25 mg/kg/day erlotinib (C) via oral gavage. Scale bars = 
50 μm. D) Quantification of the number of budding ductal structures. Every ductal structure 
distal to the lymph node was counted in H&E stained sections of the three classes of mice 
and then grouped into budding or no budding structures. At least three sections were 
analyzed per mouse. Error bars represent s.e.m. (*P<0.05) E) Cellular proliferation was 
measured by IF BrdU staining. All epithelial cells were counted in ten ductal structures per 
section by DAPI staining, and the percent BrdU-positive epithelial cells was determined. A 
minimum of 1500 cells were counted per treatment group. Error bars represent s.e.m. 
(****P<0.001) F to H) Representative images of BrdU (red) stained sections of paraffin-
embedded mammary glands from WT (F), MMTV-iFGFR1 transgenic mice treated with 1 
mg/kg AP via i.p. injections and either DMSO (G) or 25 mg/kg/day erlotinib (H) via oral 
gavage. The sections were also stained with DAPI (blue) to visualize all cells. Scale bars = 
50 μm. 
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control animals (Fig. 6A-D). Erlotinib treatment significantly reduced this 
phenotype in iFGFR1-activated mammary glands (Fig. 6A-D). Moreover, the 
severity of the aberrant budding was significantly decreased in mammary glands 
of erlotinib-treated iFGFR1-activated animals as compared to mammary glands 
of iFGFR1-activated animals not treated with erlotinib (Fig. 6D). These results 
further support that EGFR activation is required to promote iFGFR1-stimulated 
tumorigenic phenotypes and notably, that inhibition of EGFR is sufficient to 
reduce established iFGFR1-stimulated tumorigenic phenotypes. Together, these 
data indicate that EGFR might represent a novel therapeutic target in FGFR1-
amplified breast tumors. 
To ensure that the observed aberrant lateral budding is due to aberrant 
cellular proliferation and not just a rearrangement of the cellular structure of the 
ductal tree, histological sections were stained with an anti-BrdU antibody. As 
shown in Figures 5E-H and 6E-H, iFGFR1 activation in transgenic animals 
significantly increased cellular proliferation of the ductal epithelial cells as 
compared to WT controls, while erlotinib treatment of iFGFR1 transgenic mice 
significantly reduced the number of BrdU positive epithelial cells. These data 
suggest that iFGFR1-induced cellular proliferation in vivo requires activation of 
EGFR, as inhibiting the EGFR kinase domain with erlotinib treatment blocks the 
ability of the epithelial cells to proliferate. 
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Figure 6: Erlotinib reduces established FGFR1-induced mammary epithelial cell 
budding and proliferation in vivo. 
A to C) Representative images of sectioned, paraffin-embedded mammary glands stained 
with H&E. (A) WT control mice. (B) MMTV-iFGFR1 transgenic mice treated with 1mg/kg/day 
AP via i.p. injections on days 1, 5, and 9 and DMSO via oral gavage on days 10-14. (C) 
MMTV-iFGFR1 transgenic mice treated with 1mg/kg/day AP via i.p. injections on days 1, 5, 
and 9 and 25 mg/kg/day erlotinib via oral gavage on days 10-14. Scale bars = 50 μm. D) 
Quantification of the severity and total number of budding ductal structures in each treatment 
group. All ductal structures distal to the lymph node were counted in each H&E stained 
section. Severe budding structures were denoted by five or more buds. Moderate budding 
structures contained one to four buds. At least three sections were analyzed per mouse. 
Error bars represent s.e.m. (****P<0.001) E) Quantification of epithelial cell proliferation 
measured by DAPI staining to visualize all cells and IF staining of BrdU to visualize 
proliferating cells. Percent BrdU-positive epithelial cells was determined by counting all 
epithelial cells (by DAPI) and all BrdU-positive cells (red) in each of ten ductal structures per 
section. A minimum of 1500 cells were counted per treatment group. Error bars represent 
s.e.m. (****P<0.001) F to H) Representative images of sectioned, paraffin-embedded 
mammary glands stained with DAPI (blue) and for BrdU (red). (F) WT control mice. (G) 
MMTV-iFGFR1 transgenic mice treated with 1mg/kg/day AP via i.p. injections on days 1, 5, 
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and 9 and DMSO via oral gavage on days 10-14. (H) MMTV-iFGFR1 transgenic mice treated 
with 1mg/kg/day AP via i.p. injections on days 1, 5, and 9 and 25 mg/kg/day erlotinib via oral 
gavage on days 10-14. Scale bars = 50 μm.  
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2.4 Discussion  
FGFR1 is located on human chromosome 8p11-12, which is a common 
site of amplification in human breast cancers [117, 119, 125, 315]. While it is still 
not clear whether FGFR1 is the driving oncogene in this region, studies that 
focused on identification of smaller segments within the amplicon have found that 
the region containing FGFR1 is linked to poor prognosis [119]. Furthermore, 
recent studies have demonstrated that while FGFR1 may not be sufficient to 
drive tumor formation on its own, it can act in concert with genes in other co-
amplified regions, such as myc on 11q13, to promote tumorigenesis [125]. In 
agreement with this hypothesis, studies using mouse models have demonstrated 
that FGFR1 activation, in conjunction with another oncogenic signal, such as 
Wnt-1, can dramatically decrease tumor latency [314]. Moreover, recent studies 
have implicated FGFR1 in breast cancer, particularly in the resistance of breast 
cancer cells to endocrine- and chemotherapy-based treatments [120, 121]. 
Therefore, FGFR1 may represent a novel therapeutic target in breast cancer 
patients, particularly in patients that do not respond well to standard therapies. 
Based on the potential contributions of FGFR1 to breast tumorigenesis, 
we have utilized both in vitro and in vivo models to better understand the 
mechanisms by which FGFR1 promotes mammary tumor formation. Previous 
studies have demonstrated that activation of iFGFR1 in mammary epithelial cells 
in vitro results in increased proliferation, survival, migration, invasion, and EMT 
[127, 128, 312]. Furthermore, activation of iFGFR1 in mammary epithelial cells in 
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vivo leads to the formation of alveolar hyperplasias, ultimately resulting in the 
formation of tumors with both adenocarcinoma and squamous characteristics 
[127, 129]. We have further utilized these cell culture and transgenic mouse 
models to delineate the mechanisms by which FGFR1 promotes mammary tumor 
formation. Obtaining a better understanding of these mechanisms will ultimately 
lead to the development of therapeutic strategies to target tumors in breast 
cancer patients with high levels of FGFR1 and increased resistance to 
conventional therapies. 
Previous gene expression studies using microarray analysis led to the 
identification of numerous potential genes involved in promoting FGFR1-driven 
tumorigenesis [129]. Our recent studies have focused primarily on secreted 
factors regulated by FGFR1 because of the potential ability of secreted factors to 
regulate both epithelial and stromal cells. During the analysis of these studies, 
we found a significant induction of two EGF ligands, AREG and EREG, following 
iFGFR1 activation. This finding was further verified in our iFGFR1 in vitro system. 
Importantly, AREG and EREG expression was increased following iFGFR1 
activation at both the transcript and protein levels. This observation was also 
confirmed in the MCF7 human breast cancer cell line, which has been previously 
used to study FGF signaling in breast cancer cells. We chose to further evaluate 
the ability of these ligands to act through the EGFR pathway to promote FGFR1-
driven mammary tumorigenesis. 
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Both AREG and EREG have been implicated in breast cancer [19, 174, 
176, 197-199, 295]. High AREG expression has been identified in cancerous 
lesions but not in neighboring, non-cancerous tissue [169, 180, 316]. This 
expression has also been associated with large, high-grade tumors and in 
metastases found in lymph nodes, suggesting that high AREG expression is a 
marker for aggressive, invasive breast cancers [169, 180, 296]. Interestingly, 
EREG expression has also been found to correlate with breast cancer metastasis 
to the lung, suggesting that it too promotes invasive breast cancer progression 
[198, 199]. AREG is known to exclusively bind and activate EGFR [131], while 
EREG acts through both EGFR and ErbB4 [186, 187]. In these studies, we found 
that AREG and EREG were both able to induce proliferation, migration and 
activation of the ERK1/2 pathway in HC11 cells. Furthermore, AREG and EREG 
both act primarily through EGFR, as demonstrated by the inhibition of these 
phenotypes by the EGFR-specific inhibitor, erlotinib.  
Because AREG and EREG, which are both EGFR ligands, are both 
induced by iFGFR1 activation and are capable of promoting both migration and 
proliferation of the HC11 cells, we hypothesized that activation of EGFR could be 
a mechanism by which iFGFR1 promotes these phenotypes. In agreement with 
this hypothesis, our studies demonstrate that iFGFR1 activation stimulated 
phosphorylation of EGFR at tyrosine residues 845, 1068, and 1173 and that 
blocking EGFR activity inhibited iFGFR1-induced migration and proliferation. 
Moreover, investigation of different downstream molecules demonstrated that AP 
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treatment of HC11/R1 cells stimulated activation of Akt and ERK1/2 and 
expression of Cyclin D1 that was inhibited upon erlotinib treatment. However, 
analysis of other signaling pathways revealed that some signaling molecules, 
including p38 and phospholipase Cγ (PLCγ), were regulated solely by iFGFR1 
and not by EGFR (data not shown). Although erlotinib treatment significantly 
inhibited iFGFR1-driven proliferation and migration, this inhibition was not 
complete, suggesting that EGFR-independent pathways also contribute to these 
phenotypes. Therefore, it is possible that using a combination of erlotinib and 
additional inhibitors that specifically target these pathways will lead to a more 
complete inhibition of FGFR1-driven phenotypes. Overall, the results presented 
here support the hypothesis that iFGFR1 leads to activation of EGFR, which then 
contributes to the regulation of signaling pathways that promote iFGFR1-induced 
tumorigenic phenotypes.  
Because the concentration of AREG in the media was consistently higher 
than that of EREG, we predicted that AREG may be the dominant ligand 
responsible for EGFR activation. However, knockdown of Areg in the HC11/R1 
cells using shRNA strategies did not reveal any differences in iFGFR1-induced 
migration or proliferation (data not shown). Therefore, it is likely that EREG is 
able to compensate for loss of AREG and that targeting single ligands may not 
be an effective therapeutic strategy when multiple EGFR ligands are present. 
Current studies are focusing on understanding the regulation of the sheddase 
ADAM17 by FGFR1 and the ability of this protease to release of both AREG and 
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EREG into the media. Targeting the regulation of AREG and EREG release into 
the media might represent a better strategy than targeting the ligands 
themselves. 
Using a mouse model of mammary tumorigenesis, we demonstrate that 
treatment of mice with erlotinib inhibits epithelial proliferation and subsequent 
formation of early-stage hyperplastic lesions following iFGFR1-activation in vivo. 
Although our cell culture studies focused on the autocrine effects of iFGFR1-
induced activation of EGFR, it is likely that paracrine stimulation of EGFR is also 
involved in regulating the tumorigenic phenotype in vivo. For example, 
transplantation studies using different combinations of Areg and Egfr null and 
positive epithelial and stromal cell types found that, for proper mammary gland 
development, Areg expression is required in the mammary epithelial cells, while 
Egfr is required in the stromal, and not the epithelial, compartment [107, 167]. 
These data indicate that AREG can act in a paracrine manner through stromal 
EGFR to stimulate expression of growth factor(s) that can act to drive epithelial 
cell proliferation, which is necessary for proper ductal network formation within 
the mammary gland. Further studies are required to better understand the effects 
of AREG and EREG on cells within the stroma and how these interactions might 
promote tumorigenesis. 
Together, our results reveal the complex interactions between various 
signaling pathways that can regulate tumorigenesis and suggest that targeted 
therapies may need to take into account more than one pathway. To date, 
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FGFR1 inhibitors have not yet been tested in patients, although there are reports 
of FGFR1 inhibitors in preparation [317]. However, EGFR inhibitors have been 
successfully utilized in patients with certain types of cancers, including lung 
cancers [306, 307]. Therefore, inhibition of the EGFR pathway may be an 
alternative targeting strategy in breast cancer patients with high levels of FGFR1. 
Further studies are required to determine the link between FGFR1 expression 
and EGFR activation in human breast cancer tissue samples. 
In summary, we have demonstrated that the EGFR pathway is an 
important downstream regulator of FGFR1-induced mammary tumor formation. 
Growth factor receptors and their downstream signaling pathways in breast 
cancer have been the focus of numerous studies. However, these studies have 
generally focused on single pathways at a time. It is becoming clear that these 
pathways likely interact and that understanding the key points at which these 
pathways communicate is important for generating novel therapies that most 
efficiently inhibit tumor formation and progression. 
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Chapter 3: FGFR1 mediates Doxorubicin 
chemoresistance through activation of STAT3 
 
3.1 Introduction 
Breast cancer is the second leading cause of cancer-related deaths in 
women and the most frequently diagnosed type of cancer in women (American 
Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer 
Society; 2012.). Much work has been done to better understand the complexity 
and heterogeneity of breast cancer, and in the past decade, breast cancer has 
been categorized into six intrinsically distinct molecular subtypes [52-55]. While 
these subtypes have greatly improved our understanding of the disease, they 
have not yet been translated into functionally useful contexts in the clinical 
setting. Instead, in the clinic, treatment plans are determined based on 
expression of the hormone receptors (HRs), estrogen receptor (ER) and 
progesterone receptor (PR), and the growth factor receptor, HER2/ErbB2/neu. 
Breast cancers that do not express any of these receptors are termed triple 
negative (TN). While targeted therapies against the HRs and HER2 are used for 
patients with cancers expressing these receptors, the lack of these targets 
precludes their use in TN breast cancers (TNBCs). Alternatively, TNBCs are 
treated with systemic chemotherapies, which function by inducing apoptosis in a 
non-directed manner [50, 51]. Notably, while some patients do respond well to 
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chemotherapy, most do not achieve pathologic complete response (pCR), and 
eventually stop responding to chemotherapy. Therefore, identification of 
alternative targets commonly expressed in TNBCs is a current focus of study. 
The genomic locus of fibroblast growth factor receptor 1 (FGFR1), 8p11-
12, is amplified in approximately 10% of all breast cancers [114-117]. Studies 
have demonstrated that FGFR1-containing 8p11-12 amplification correlates with 
poor patient prognosis and increased metastatic development [116, 119-121]. 
Moreover, patients harboring an 8p11-12 amplification and who had undergone 
aggressive treatment plans had poorer outcome than patients that had 
undergone aggressive treatment plans but did not harbor 8p11-12 amplification, 
suggesting that FGFR1 might represent a good therapeutic target for patients 
with drug resistant breast cancers [120]. Interestingly, FGFR1 amplification is 
commonly found in luminal A and luminal B breast cancer subtypes, which are 
largely HR+ breast cancers, and studies using FGFR1-amplified breast cancer 
cell lines demonstrate that FGFR1 amplification mediates endocrine therapy 
resistance that can be reduced by using siRNA against FGFR1  [120, 121]. 
Furthermore, a number of TNBC cell lines appear to be dependent on FGFR 
signaling, as inhibition of FGFR signaling with the small molecule inhibitor, 
PD173074, or siRNAs results in decreased cell growth in vitro and in vivo [123]. 
Studies using a previously engineered inducible FGFR1 (iFGFR1) system have 
further ascertained that iFGFR1 activation in mouse mammary epithelial cells 
results in decreased apoptosis and increased cell growth, proliferation, and 
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survival [127, 128]. Taken together, these studies suggest that FGFR1 is 
involved in mediating therapeutic resistance by promoting cell survival and 
inhibiting apoptosis, and led us to hypothesize that FGFR1 signaling mediates 
chemoresistance. 
Previously, we have shown that iFGFR1 signaling requires epidermal 
growth factor receptor (EGFR) activation to stimulate increased proliferation, 
migration, and extracellular signal-regulated kinase 1/2 (ERK1/2) activation in 
mammary epithelial cells [318]. EGFR is expressed in 50-70% of basal-like 
and/or TNBCs, and patients with TN tumors that do express EGFR have worse 
prognosis than those who do not [68, 72, 73, 232]. Additionally, clinical trials to 
determine if there is a benefit to adding EGFR inhibitors with chemotherapy 
regimens have commenced [50]. Together, these studies indicate that EGFR 
might be a valuable target downstream of FGFR1 in mediating TNBC 
chemoresistance. 
Another factor that has been indicated to mediate breast cancer 
chemoresistance is signal transducer and activator of transcription 3 (STAT3). 
STAT3 has been reported to be constitutively activated in a number of cancers, 
including 50-60% of all breast cancers [264-270]. Several studies have found that 
STAT3 constitutive activation occurs in chemoresistant tumors and that inhibition 
of STAT3 re-establishes chemosensitivity of breast cancer cell lines [269, 282-
284]. Because of its role as a transcription factor, aberrant activation of STAT3 
leads to increased expression of many genes that act to promote tumorigenesis, 
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such as Cyclin D1, c-myc, and several matrix metalloproteases (MMPs) [269, 
276]. In breast cancer cell lines, STAT3 activation has been shown to increase 
proliferation, migration, and invasion [266, 271, 275, 278]. Alternatively, inhibition 
of STAT3 leads to decreased growth and metastatic ability of breast cancer cell 
lines [272, 273, 277]. Studies have also demonstrated that inhibition of STAT3 
increases apoptosis [281, 283]. Notably, inhibition of Janus kinases (JAKs) or 
glycoprotein-130 (gp130) can also block STAT3 activation and induce 
chemosensitivity and apoptosis, suggesting that STAT3 activation in breast 
cancers is stimulated via cytokine signaling through gp130/JAK [270-272, 277, 
282, 283]. 
In the present study, we demonstrate that FGFR1 activation decreases 
responsiveness of mammary epithelial and breast cancer cells to the 
chemotherapeutic agent, Doxorubicin. Inhibiting FGFR1 with the small molecule 
inhibitor, PD173074, both in vitro and in vivo results in increased 
chemosensitivity and apoptosis. We also show that FGFR1 and EGFR are co-
expressed in a panel of TNBC cell lines. Interestingly, while our data suggest that 
inhibiting EGFR increases chemosensitivity, it appears that FGFR1-induced 
chemoresistance is only partially mediated through EGFR signaling. Conversely, 
we demonstrate that FGFR1 signaling indirectly activates STAT3 through 
iFGFR1-induced expression of leukemia inhibitory factor (LIF), which 
subsequently signals through gp130. Furthermore, we show that inhibition of 
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STAT3 with the small molecule inhibitor, Stattic, restores mouse mammary 
epithelial cell chemosensitivity to Doxorubicin in vitro.  
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3.2 Materials and Methods 
3.2.A Cell culture. 
Generation of HC11/R1 cells has been described previously [128], and 
HC11/R1 and HC11 cells were obtained from Dr. Jeff Rosen (Baylor College of 
Medicine, Houston, TX, USA). HC11/R1 cells were maintained in HC11/R1 
complete media [serum free (SF)-RPMI (Invitrogen, Carlsbad, CA, USA) 
supplemented with final percentages/concentrations of 10% FBS (Invitrogen), 1% 
Pen Strep (Invitrogen), 5 μg/mL Insulin (Sigma-Aldrich Corporation, St. Louis, 
MO, USA), 10 ng/mL EGF (Invitrogen), and 0.7 μg/mL Puromycin (Sigma-Aldrich 
Corporation)]. HC11 cells were maintained in HC11 complete media (HC11/R1 
complete media without Puromycin). Hs578T cells were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained 
in Hs578T complete media [SF-DMEM (Invitrogen) supplemented with final 
percentages of 10% FBS and 1% Pen Strep]. MCF10A cells were obtained from 
ATCC and maintained in DMEM/F12 (Lonza, Allendale, NJ, USA), supplemented 
with final percentages/concentrations of 5% horse serum (Invitrogen), 1% Pen 
Strep, 10 μg/mL Insulin, 0.5 μg/mL Hydrocortisone (Sigma-Alrich Corporation), 
100 ng/mL Cholera toxin (Sigma-Alrich Corporation), 20 ng/mL EGF. MDA-MB-
231 cells were obtained from ATCC and maintained in SF-DMEM/F12 
supplemented with final percentages of 10% FBS and 1% Pen Strep. MDA-MB-
468 cells were obtained from ATCC and maintained in SF-DMEM supplemented 
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with final percentages of 10% FBS and 1% Pen Strep. All cells were grown and 
maintained at 37°C in 5% CO2. 
 
3.2.B ApoTox-Glo assays. 
HC11/R1 or HC11 cells were plated in 96 well white-wall, clear-bottom 
plates at a concentration of 5000 cells in 100 μL complete media per well. Two 
days later, the complete media was removed, each well was rinsed with 1xPBS 
(Cellgro, Manassas, VA, USA), and the cells were starved overnight in SF-RPMI. 
The next day, 30 nM B/B (Clontech, Mountain View, CA, USA) or its ethanol 
solvent was added to each well of HC11/R1 cells. HC11 cells were treated with 
fresh HC11/R1 conditioned media or 20 ng/mL recombinant mouse (rm)AREG 
(R&D Systems, Minneapolis, MN, USA) or its solvent control 1xPBS following 
overnight starvation. To obtain HC11/R1 conditioned media, HC11/R1 cells were 
plated in 10 cm dishes and grown to confluence. Confluent cells were rinsed 
twice with 1xPBS and starved overnight in SF-RPMI. Starved cells were treated 
with either 30 nM B/B or its ethanol solvent overnight to condition the media. At 
the time of B/B, HC11/R1 conditioned media, or rmAREG treatment, 2 μM 
Doxorubicin (Boynton Pharmacy, University of Minnesota, Minneapolis, MN, 
USA) or saline (0.9% sodium chloride (Amresco, Solon, OH, USA) in milliQ-water 
and then filter sterilized) as a solvent control and/or 1 μM erlotinib (Boynton 
Pharmacy) or DMSO (Sigma-Aldrich Corporation) as a solvent control was added 
as indicated. All treatments were done in at least biological triplicates. Using the 
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ApoTox-Glo assay from Promega (Madison, WI, USA) according to the 
manufacturer’s protocol, apoptosis and viability were assessed 20 hours after 
treatment. Results are displayed as the average fold change in apoptosis relative 
to viability. Experiments were performed at least three separate times. Statistical 
analysis was performed using the unpaired student’s t-test to compare two 
means (GraphPad QuickCalcs, GraphPad Software, Inc., CA, USA). 
 
3.2.C TUNEL assays. 
Cells were plated on poly-L-ornithine hydrobromide-coated (at 500 μg/mL, 
Sigma-Aldrich Corporation) 12 mm circular glass cover slips placed one per well 
in 24 well plates. Cells were allowed to grow to 80-90% confluency before rinsing 
twice with 1xPBS and then starving overnight in SF-media. Starved HC11/R1 
cells were treated with either 30 nM B/B or ethanol and either 2 μM Doxorubicin 
or saline for 20 hours. Where indicated, 4 μM Stattic (Sigma-Aldrich Corporation) 
or its DMSO solvent was also added to the media for the same 20 hours. Starved 
HC11 cells were treated with fresh HC11/R1 conditioned media (acquired as 
described in the previous section) and either 2 μM Doxorubicin or saline for 20 
hours. Starved Hs578T cells were treated for 20 hours with 50 ng/mL basic 
(b)FGF (Invitrogen) and either 2 μM Doxorubicin or saline. Alternatively, Hs578T 
cells grown to 80-90% confluency were treated with 1 μM PD173074 or its 
DMSO solvent in the complete Hs578T media overnight. The next day, the media 
was replaced with fresh complete Hs578T media supplemented with 1 μM 
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PD173074 or DMSO and either 2 μM Doxorubicin or saline for 20 hours. At 20 
hours post treatment, the media was removed and replaced with 300 μL 4% PFA 
for 25 minutes at 4°C. Fixed cells were then stained using the DeadEnd 
Fluorometric TUNEL System (Promega) according to the manufacturer’s protocol 
with the minor change that the staining protocol was carried out while the 
cells/coverslips were still in the wells of the 24 well plate because the cells were 
grown on small coverslips instead of slides. The cells/coverslips were mounted 
onto slides using ProLong® Gold antifade reagent with DAPI (Invitrogen) to 
visualize the nuclei. Five representative pictures were taken of each treatment 
using Leica LAS software, and all cells (nuclei) and TUNEL-positive cells were 
counted in a blinded manner for each of the five pictures per treatment to obtain 
percent TUNEL positive cells. Experiments were performed at least three 
separate times. Statistical analysis was performed using the unpaired student’s t-
test to compare two means (GraphPad QuickCalcs). 
 
3.2.D Transplant studies. 
Three to four week old Balb/c female mice were purchased from Harlan 
Laboratories (Indianapolis, IN, USA). 200,000 HC11/R1 cells in a total volume of 
10 μL 50% 1xPBS:50% Matrigel (BD Biosciences, San Jose, CA, USA) were 
injected into the cleared fat pads of the fourth inguinal mammary gland of 
anesthetized mice. 200,000 HC11 cells in a total volume of 10 μL 50% 
1xPBS:50% Matrigel were injected into the contralateral cleared fat pads of the 
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fourth inguinal mammary gland of anesthetized mice as a control. Four days 
post-transplant surgeries, all mice were started on twice weekly intraperitoneal 
(i.p.) injections of 1 mg/kg/day B/B to activate iFGFR1. Mice were palpated daily 
for the presence of tumor formation, and once tumors became measurable, they 
were measured daily using a caliper. When tumors reached at least 100mm3, 
mice were administered 10 mg/kg/day Doxorubicin or an equivalent volume of 
saline via tail vein injection once weekly. Additionally, mice were treated with 25 
mg/kg/day PD173074 or an equivalent volume of the 50 mM Lactate Buffer 
solvent via i.p. injections five out of seven days of the week. Three mice were in 
each treatment group. Mice were sacrificed at two weeks, when tumors reached 
a volume of 1cm3, or when tumors became too small to measure. Two hours 
before sacrificing, mice were given i.p. injections of 0.3 mg/kg BrdU (GE 
Healthcare Life Sciences, Piscataway, NJ, USA). At the time of sacrifice, the 
fourth inguinal mammary glands/tumors were harvested for further analysis. All 
animal care and procedures were approved by the Institutional Animal Care and 
Use Committee of the University of Minnesota and were in accordance with the 
procedures detailed in the Guide for Care and Use of Laboratory Animals. 
 
3.2.E TUNEL in vivo staining. 
Glands/tumors were fixed in fresh 4% PFA for 2 hours on ice and then 
stored in 70% ethanol at 4°C until embedded in paraffin and sectioned at 5 μm. 
For apoptosis analysis, 5 μm sections were stained using the DeadEnd 
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Flourometric TUNEL System (Promega) according to the manufacturer’s 
protocol. All sections were mounted in ProLong® Gold antifade reagent with DAPI 
to visualize the nuclei. Three sections per mouse were TUNEL stained. Five 
representative pictures were taken of each section. Based on DAPI staining, all 
cells within each picture were counted (using ImageJ software) and all TUNEL 
positive cells of the same picture were counted (using Leica LAS software) to 
determine percent TUNEL positive cells. A minimum of 33,000 cells were 
counted per treatment group, and all studies were performed in a blinded 
manner. Statistical analysis was performed using the unpaired student’s t-test to 
compare two means (GraphPad QuickCalcs). 
 
3.2.F Immunoblot analysis. 
HC11/R1 or Hs578T cells were plated in six well plates in complete media, 
grown to confluence, and then starved overnight in SF-RPMI or SF-DMEM, 
respectively. The next day, HC11/R1 cells were treated with either 30 nM B/B or 
ethanol for the indicated times (Fig. 11A) or for 6 hours (Fig. 11D). Where 
designated, α-LIF (at 4 ng/mL, 40 ng/mL, and 0.4 μg/mL) or α-gp130 (at 50 
ng/mL, 0.5 μg/mL, and 5 μg/mL) neutralizing antibodies (R&D Systems, 
Minneapolis, MN, USA) were added to the media at the time of B/B treatment. 
Starved Hs578T cells were treated with 50 ng/mL bFGF for the indicated times. 
Additionally, MCF10A, Hs578T, MDA-MB-231, and MDA-MB-468 cells were 
grown to confluence in 10 cm dishes in complete media before collecting lysates. 
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Following all treatments, lysates were collected in RIPA buffer, and total protein 
concentration was determined using a D/C Protein Assay (BioRad, Hercules, CA, 
USA) assay. Thirty μg protein was analyzed on an SDS-PAGE gel, and 
immunoblotting for FGFR1 (1:1000, 3472, Cell Signaling Technology, Danvers, 
MA, USA), EGFR (1:100,000, ab52894, Abcam, Cambridge, MA, USA), or 
phosphorylated (p)STAT3 at Y705 (1:1000, 9131, Cell Signaling Technology) 
was performed. Additionally, 5 μg protein was analyzed on an SDS-PAGE gel, 
and immunoblotting for total STAT3 (1:1000, 9132, Cell Signaling Technology) 
was performed. Before immunotblotting for FGFR1 and EGFR, Ponceau S (MP 
Biomedicals, LLC, Solon, OH, USA) staining was performed according to 
standard protocols on the membranes to ensure equal loading. 
 
3.2.G ELISA analysis.  
HC11/R1 cells were plated in six well plates in complete media, grown to 
confluence, and then serum-starved overnight. Following serum starvation, cells 
were treated with either 30 nM B/B or an equivalent amount of ethanol for 24 
hours. Conditioned media were collected and used to quantify LIF protein 
concentration using an ELISA kit (R&D Systems) performed according to the 
manufacturer’s protocol. Experiments were performed in biological duplicates. 
Statistical analysis was performed using the unpaired student’s t-test to compare 
two means (GraphPad QuickCalcs). 
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3.3 Results 
3.3.A iFGFR1 activation inhibits apoptosis of mouse mammary epithelial 
cells in vitro 
Previously, it was shown that activation of iFGFR1 in the mouse mammary 
epithelial cell line HC11/R1 reduces the ability of these cells to undergo cell 
death as compared to controls with no iFGFR1 activation [128]. We verified these 
results using an ApoTox-Glo assay from Promega, which measures apoptosis, 
viability, and cytotoxicity all within the sample. As expected, after 20 hours of B/B 
treatment following overnight serum starvation, HC11/R1 cells undergo 
significantly less apoptosis than HC11/R1 cells treated with ethanol, the B/B 
solvent control (Fig. 7A). Because inhibition of FGFR signaling has recently been 
shown to inhibit survival of basal-like and TNBCs and FGFR1 has been 
associated with resistance to available breast cancer therapies, we hypothesized 
that FGFR1 activation promotes chemoresistance [121, 123]. Doxorubicin is a 
canonical anthracycline-based chemotherapy frequently used in the clinic to treat 
women with TNBCs [50, 51]. Therefore, we treated HC11/R1 cells with 
Doxorubicin in conjunction with either B/B or ethanol treatment for 20 hours and 
again performed an ApoTox-Glo assay. As seen in Figure 7A, while Doxorubicin 
significantly increases the amount of apoptosis of ethanol-treated HC11/R1 cells, 
there is still a significant reduction in iFGFR1-activated HC11/R1 cell death even 
with Doxorubicin treatment. These results were confirmed using a second 
method to detect cells undergoing apoptosis, TUNEL (Fig. 7C and 7E). Together, 
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these data suggest that FGFR1 signaling confers mammary epithelial cells a 
protection from programmed cell death.  
As we have previously shown that iFGFR1 activation results in increased 
secretion of proteins such as the growth factor ligands AREG and EREG, we 
wanted to examine whether the FGFR1-mediated inhibition of apoptosis occurred 
through secreted factors [318]. For that reason, we incubated HC11 cells, which 
do not express the iFGFR1 construct, with fresh conditioned media from 
HC11/R1 cells treated overnight with either B/B or ethanol. Figure 7B shows that 
HC11 cells treated with conditioned media from iFGFR1-activated HC11/R1 cells 
still undergo significantly less apoptosis than HC11 cells incubated in conditioned 
media from ethanol-treated HC11/R1 cells. Interestingly, HC11 cells incubated in 
conditioned media from ethanol-treated HC11/R1 cells underwent significantly 
more apoptosis when Doxorubicin was added to the HC11 cells as compared to 
no Doxorubicin treatment (Fig. 7B). However, HC11 cells incubated in iFGFR1-
activated HC11/R1 conditioned media were significantly protected from 
Doxorubicin-induced apoptosis as compared to HC11 cells incubated in the 
ethanol-treated conditioned media and treated with Doxorubicin (Fig. 7B). These 
results were also confirmed using TUNEL staining (Fig. 7D and 7F). These data 
suggest that activating iFGFR1 results in the secretion of factors that confer 
protection of these cells from apoptosis in an autocrine manner. 
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Figure 7: iFGFR1 activation reduces apoptosis in mouse mammary epithelial cells. 
A) Quantification of apoptosis as detected by ApoTox-Glo assay of serum-starved HC11/R1 
cells following 20 hours of treatment with 30 nM B/B or its ethanol solvent and either 2 μM 
Doxorubicin or its saline solvent. Results are shown as average fold change in apoptosis 
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normalized to viability. Experiments were conducted in biological triplicate and performed 
three individual times. Error bars represent s.e.m. (***P<0.005, ****P<0.001) B) 
Quantification of apoptosis as detected by ApoTox-Glo assay of serum-starved HC11 cells 
incubated in HC11/R1 conditioned media for 20 hours. Conditioned media was obtained by 
treating serum-starved HC11/R1 cells with 30 nM B/B or ethanol overnight. Additionally, 
either 2 μM Doxorubicin or saline was added to the HC11 cells at the time of conditioned 
media treatment. Results are shown as average fold change in apoptosis normalized to 
viability. Experiments were conducted in biological triplicate and performed three individual 
times. Error bars represent s.e.m. (***P<0.005, ****P<0.001) C) Quantification of apoptosis 
as detected by TUNEL positive staining in serum-starved HC11/R1 cells after 20 hours of 
treatment with 30 nM B/B or ethanol and either 2 μM Doxorubicin or saline. Five 
representative images of each treatment were taken, and all cells were counted using DAPI 
to identify nuclei. TUNEL positive cells in each picture were also counted, and percent 
TUNEL positive cells was determined. Results are shown as average fold change of TUNEL 
positive cells relative to total cell number. Experiments were performed three individual 
times, and cells were counted in a blinded manner. Error bars represent s.e.m. (***P<0.005, 
****P<0.001) D) Quantification of apoptosis as detected by TUNEL positive staining in 
serum-starved HC11 cells after 20 hours of treatment with HC11/R1 conditioned media. 
HC11/R1 conditioned media was obtained as in (B). At the time of conditioned media 
treatment, HC11 cells were also given either 2 μM Doxorubicin or saline. Five representative 
images of each treatment were taken, and all cells were counted using DAPI to identify 
nuclei. TUNEL positive cells in each picture were also counted, and percent TUNEL positive 
cells was determined. Results are shown as average fold change of TUNEL positive cells 
relative to total cell number. Experiments were performed three individual times, and cells 
were counted in a blinded manner. Error bars represent s.e.m. (*P<0.05, ***P<0.005, 
****P<0.001) E) Representative images of TUNEL staining in serum-starved HC11/R1 cells 
following 20 hours of treatment with 30 nM B/B or ethanol and either 2 μM Doxorubicin or 
saline. TUNEL positive cells are circled. DAPI = blue, TUNEL = green. All pictures were 
taken at 40x magnification. F) Representative images of TUNEL staining in serum-starved 
HC11 cells following 20 hours of treatment with HC11/R1 conditioned media and either 2 μM 
Doxorubicin or saline. TUNEL positive cells are circled. DAPI = blue, TUNEL = green. All 
pictures were taken at 40x magnification. 
  
  103 
3.3.B FGFR signaling inhibits apoptosis of a TNBC cell line 
To validate the importance of FGFR1 signaling in chemoresistance, we 
used the human TNBC cell line Hs578T. This cell line is dependent on FGFR 
signaling, and it has previously been shown that the FGFR inhibitor, PD173074, 
reduces cell growth in these cells [123]. Treatment of Hs578T cells with 
PD173074 resulted in an increase in apoptosis as compared to cells treated with 
the DMSO solvent control as detected by TUNEL staining (Fig. 8A and 8C). 
Additionally, while Hs578T cells growing in complete media had a partial 
response to Doxorubicin treatment, PD173074 treatment significantly increased 
Hs578T cell Doxorubicin-induced apoptosis (Fig. 8A and 8C). Furthermore, when 
we first starved the Hs578T cells and then subsequently treated with bFGF to 
activate FGFR signaling, we observed a significant decrease in apoptosis of 
these cells as compared to no treatment control cells (Fig. 8B and 8D). These 
results are in line with iFGFR1 activation in HC11/R1 cells as described above. 
Whereas Doxorubicin significantly increased apoptosis in the no treatment 
starved cells, FGFR signaling activation with bFGF significantly reduced the 
ability of Hs578T cells to undergo apoptosis as detected by TUNEL staining (Fig. 
8B and 8D). These results demonstrate a role of FGFR1 in the inhibition of TNBC 
cell death, and furthermore, they provide evidence that FGFR1 signaling 
promotes chemoresistance that can be reversed by inhibiting FGFR1.  
 
  104 
 
 
Figure 8: FGFR1 signaling reduces apoptosis in a TNBC cell line. 
A) Quantification of apoptosis as detected by TUNEL positive staining in Hs578T cells in 
complete media after 20 hours of treatment with 1 μM PD173074 or its DMSO solvent and 
either 2 μM Doxorubicin or saline. Five representative images of each treatment were taken, 
and all cells were counted using DAPI to identify nuclei. TUNEL positive cells in each picture 
were also counted, and percent TUNEL positive cells was determined. Results are shown as 
average percent TUNEL positive cells relative to total cell number. Experiments were 
performed three individual times, and cells were counted in a blinded manner. Error bars 
represent s.e.m. (***P<0.005, ****P<0.001) B) Quantification of apoptosis as detected by 
TUNEL positive staining in serum-starved Hs578T cells after 20 hours of treatment with 50 
ng/mL bFGF and either 2 μM Doxorubicin or its saline solvent. Five representative images of 
each treatment were taken, and all cells were counted using DAPI to identify nuclei. TUNEL 
positive cells in each picture were also counted, and percent TUNEL positive cells was 
determined. Results are shown as average percent TUNEL positive cells relative to total cell 
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number. Experiments were performed three individual times, and cells were counted in a 
blinded manner. Error bars represent s.e.m. (*P<0.05, ****P<0.001) C) Representative 
images of TUNEL staining in Hs578T cells in complete media following 20 hours of treatment 
with 1 μM PD173074 or its DMSO solvent and either 2 μM Doxorubicin or saline. TUNEL 
positive cells are circled. DAPI = blue, TUNEL = green. All pictures were taken at 40x 
magnification. D) Representative images of TUNEL staining in serum-starved Hs578T cells 
following 20 hours of treatment with 50 ng/mL bFGF and either 2 μM Doxorubicin or saline. 
TUNEL positive cells are circled. DAPI = blue, TUNEL = green. All pictures were taken at 
40x magnification.  
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3.3.C Inhibition of iFGFR1 in vivo increases Doxorubicin-induced apoptosis 
Since the complexity of tumor formation and chemoresistance is not fully 
recapitulated in vitro, we examined whether inhibition of FGFR1 in vivo resulted 
in increased chemosensitivity. Three to four week old Balb/c female mice were 
transplanted with HC11/R1 cells in the cleared fat pads of the fourth inguinal 
mammary glands and subsequently injected with B/B twice weekly to activate 
iFGFR1. As a control, HC11 cells were injected into the cleared fat pads of the 
fourth inguinal mammary glands on the contralateral side. Mice were monitored 
for tumor formation and growth, and once tumors reached at least 100mm3, mice 
were treated with either Doxorubicin or saline as well as with either PD173074 or 
50 mM Lactate Buffer. Control animals (treated with saline and Lactate Buffer), 
had steady tumor growth (Fig. 9A). Notably, mice treated with both Doxorubicin 
and PD173074 had significantly less tumor burden than control animals. 
Combined treatment resulted in immediate response and ultimately a decrease in 
tumor burden in these animals. While mice given Doxorubicin and Lactate Buffer 
or mice given saline and PD173074 did eventually start responding to the 
individual treatments, there was not a significant difference in tumor burden in 
these mice as compared to control animals.  
Because chemotherapies act by inducing cell death, we investigated the 
levels of apoptosis in the collected tumors. As shown in Figure 9B, mice treated 
with both Doxorubicin and PD173074 had significantly more cells undergoing 
apoptosis as assessed via TUNEL staining than control or individually treated  
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Figure 9: Inhibition of iFGFR1 increases Doxorubicin chemosensitivity in vivo. 
A) Three to 4 week old Balb/c female mice were injected with 200,000 HC11/R1 cells into the 
cleared fat pads of the fourth inguinal mammary gland. Mice were given twice weekly 
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injections of 1mg/kg/day B/B to activate iFGFR1 and palpated daily for tumor formation. 
Once tumors reached at least 100mm3, mice were treated with either 10 mg/kg/day 
Doxorubicin or an equivalent volume of saline via tail vein injection once weekly and either 
25 mg/kg/day PD173074 or an equivalent volume of the 50 mM Lactate Buffer solvent via i.p. 
injections five out of seven days of the week. Graph depicts average tumor volume for each 
treatment group at days 1, 4, and 8 of treatment. Each treatment group contained three 
mice. Error bars represent s.e.m. (*P<0.05) B) Quantification of TUNEL staining of tumor 
sections for each treatment group. Tumors were sectioned, and three sections of each 
mouse were stained with TUNEL and DAPI. Five representative pictures of each section 
were taken. Total cell number was determined for each picture using ImageJ software, and 
the number of TUNEL positive cells was also counted for each picture. Graph shows 
average percent TUNEL positive cells for each treatment group. Error bars represent s.e.m. 
(****P<0.001) C) Quantification of BrdU IF staining of tumor sections for each treatment 
group. Tumors were sectioned, and three sections of each mouse were stained for BrdU and 
DAPI. Five representative pictures of each section were taken. Total cell number was 
determined for each picture using ImageJ software, and the number of BrdU positive cells 
was also counted for each picture. Graph shows average percent BrdU positive cells for 
each treatment group. Error bars represent s.e.m. (****P<0.001)  
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animals, suggesting that inhibition of FGFR1 signaling confers increased 
chemosensitivity. 
 
3.3.D Inhibiting EGFR partially restores Doxorubicin-induced apoptosis of 
mouse mammary epithelial cells 
Like FGFR1, EGFR has recently been identified as a potential druggable 
target of basal-like/TNBCs. Accordingly, we wanted to test whether EGFR is also 
involved in acquisition of chemoresistance in FGFR1-activated mammary 
epithelial cells, so we first examined FGFR1 and EGFR expression in a small 
panel of TNBC cell lines. As shown in Figure 10A, FGFR1 and EGFR are both 
expressed in all TN cell lines tested, indicating that FGFR1 and EGFR signaling 
may cooperate in the attainment of chemoresistance. 
Previously, we demonstrated that activation of FGFR1 leads to increased 
expression of the EGFR ligands AREG and EREG [318]. These ligands then 
signal in an autocrine manner through EGFR to promote the FGFR1-induced 
increase in mammary epithelial cell proliferation and migration. The EGFR kinase 
inhibitor, erlotinib, could significantly reduce the aberrant proliferation and 
migration stimulated upon iFGFR1 activation, providing evidence that EGFR 
signaling is required for FGFR1-mediated tumorigenic processes [318]. To 
determine the effect of EGFR activation in mediating chemoresistance, we used 
rmAREG to stimulate EGFR activation in HC11 cells. While rmAREG treatment 
reduced the amount of HC11 cell death detected by ApoTox-Glo assay as 
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compared to PBS-treated control cells, erlotinib treatment completely abolished 
this apoptosis reduction (Fig. 10B). Additionally, Doxorubicin in combination with 
erlotinib increases apoptosis in both rmAREG- and PBS-treated HC11 cells. 
However, EGFR activation could block Doxorubicin-induced apoptosis as 
compared to PBS-treated controls. These results suggest that EGFR may be an 
important target for increasing sensitivity to chemotherapies.  
To explore this further, we used ApoTox-Glo assays to assess whether 
inhibiting EGFR could reverse the reduction in apoptosis seen in iFGFR1-
activated mammary epithelial cells. As expected, HC11/R1 cells treated with B/B 
underwent significantly less apoptosis as compared to ethanol-treated controls, 
even in the presence of Doxorubicin (Fig. 10C). Erlotinib treatment alone did not 
significantly induce apoptosis in ethanol-treated control cells, nor did it eradicate 
the reduced levels of apoptosis in B/B-treated HC11/R1 cells. Interestingly 
though, combined Doxorubicin and erlotinib treatment induced more cell death in 
HC11/R1 cells treated with ethanol and modestly increased apoptosis in iFGFR1-
activated HC11/R1 cells as compared to cells treated with Doxorubicin only. 
Similar results were obtained when HC11 cells were incubated in HC11/R1 
conditioned media. B/B-treated HC11/R1 conditioned media protected HC11 
cells from Doxorubicin-induced apoptosis, suggesting that FGFR1 mediates 
chemoresistance through the secretion of soluble factors (Fig. 10D). Erlotinib 
treatment conferred only a slight increase in apoptosis in cells incubated in 
conditioned media from iFGFR1-activated HC11/R1 cells. All together, these  
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Figure 10: EGFR is partially responsible for FGFR1-mediated chemoresistance. 
A) Cells were grown to confluence in complete media and whole cell lysates were collected 
and analyzed by immunoblot for expression of FGFR1 and EGFR. Bottom panels show 
Ponceau S staining of the membrane for loading control. B) Quantification of apoptosis as 
detected by ApoTox-Glo assay of serum-starved HC11 cells treated with 20 ng/mL rmAREG 
or its PBS solvent control for 20 hours. Cells were also treated with either 2 μM Doxorubicin 
or saline and either 1 μM erlotinib or its solvent control DMSO. Results are shown as 
average fold change in apoptosis normalized to viability. Experiments were conducted in 
biological triplicate and performed three individual times. Error bars represent s.e.m. 
(*P<0.05, ***P<0.005, ****P<0.001) C) Quantification of apoptosis as detected by ApoTox-
Glo assay of serum-starved HC11/R1 cells treated with 30 nM B/B or ethanol for 20 hours. 
Cells were also treated with either 2 μM Doxorubicin or saline and either 1 μM erlotinib or 
DMSO. Results are shown as average fold change in apoptosis normalized to viability. 
Experiments were conducted in biological triplicate and performed three individual times. 
Error bars represent s.e.m. (**P<0.01, ***P<0.005, ****P<0.001) D) Quantification of 
apoptosis as detected by ApoTox-Glo assay of serum-starved HC11 cells incubated in 
HC11/R1 conditioned media for 20 hours. Conditioned media was obtained by treating 
serum-starved HC11/R1 cells with 30 nM B/B or ethanol overnight. At time of conditioned 
media treatment, HC11 cells were also treated with either 2 μM Doxorubicin or saline and 
either 1 μM erlotinib or its solvent control DMSO. Results are shown as average fold change 
in apoptosis normalized to viability. Experiments were conducted in biological triplicate and 
performed three individual times. Error bars represent s.e.m. (***P<0.005, ****P<0.001) 
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results suggest that, in cells that do not have FGFR1 activation, EGFR may be 
an important target for increasing sensitivity to chemotherapies but provide 
evidence against strong cooperation between FGFR1 and EGFR signaling in 
chemoresistance. 
 
3.3.E FGFR1 induces activation of STAT3 
The results described above indicate that FGFR1-mediated 
chemoresistance is not fully dependent on EGFR activation. Therefore, FGFR1 
must activate other signaling molecules whose induction interferes with 
chemotherapy-induced cell death. Recently, STAT3 has been implicated in 
chemoresistance and reduced apoptosis in a number of breast cancer cell lines 
[281-284]. Consequently, we next determined whether FGFR1 signaling 
regulates STAT3 activation. HC11/R1 cells were treated with B/B or ethanol over 
a 24 hour time course. Whole cell lysates were collected at regular intervals, and 
immunoblotting for pSTAT3 was performed. As seen in Figure 11A, iFGFR1 
activation results in increased pSTAT3 by 2 hours that is sustained at least 24 
hours. This same STAT3 activation pattern is detected in the human TNBC cells, 
Hs578T, treated with bFGF to activate FGFR signaling (Fig. 11B). Because 
STAT3 activation is not stimulated immediately following FGFR1 activation (data 
not shown) as would be expected if STAT3 directly binds to FGFR1, we next 
sought to ascertain what the STAT3 activation signaling axis is in our system. 
Canonical STAT3 activation occurs via cytokine signaling through gp130/JAK. In 
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the mammary gland, LIF and oncostatin M (OSM) are known cytokine regulators 
of STAT3 activation [262, 263]. Furthermore, LIF expression is upregulated in 
HC11/R1 cells following iFGFR1 activation as assessed via ELISA (Fig. 11C). 
Therefore, we used neutralizing antibodies against LIF and gp130 to determine 
whether cytokine signaling through gp130 induces pSTAT3 in our system. As 
seen in Figure 11D, HC11/R1 cells treated with B/B and increasing amounts of α-
LIF or α-gp130 for 6 hours, have reduced pSTAT3 levels in a dose-dependent 
fashion as compared to B/B treatment alone. To examine if STAT3 activation 
confers chemoresistance, we used the STAT3 inhibitor, Stattic, and performed 
TUNEL analysis on HC11/R1 cells. Interestingly, inhibition of STAT3 alone is not 
sufficient to induce increased apoptosis, but blocking STAT3 in Doxorubicin-
treated iFGFR1-activated HC11/R1 cells significantly abolishes the block in 
apoptosis seen in Doxorubicin-treated iFGFR1-activated HC11/R1 cells (Fig. 
11E). These results suggest that FGFR1 indirectly mediates STAT3 activation 
which then ultimately confers chemoresistance in FGFR1-activated mammary 
epithelial cells.  
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Figure 11: FGFR1 mediates Doxorubicin chemoresistance by activating STAT3. 
A) Serum-starved HC11/R1 cells were treated with either 30 nM B/B or ethanol for the 
indicated times. Following treatment, whole cell lysates were collected and analyzed by 
immunoblot for pSTAT3 and total STAT3. B) Serum-starved Hs578T cells were treated with 
50 ng/mL bFGF or not treated for the indicated times. Following treatment, whole cell lysates 
were collected and analyzed by immunoblot for pSTAT3 and total STAT3. C) To detect 
secreted LIF protein, ELISA analysis was performed on conditioned HC11/R1 media. Serum-
starved HC11/R1 cells were treated with either 30 nM AP or its ethanol solvent for 24 hours 
to condition the media. Experiments were performed in biological duplicates. Error bars 
represent s.e.m. (****P<0.001) D) Serum-starved HC11/R1 cells were treated with either 30 
nM B/B or ethanol for 6 hours. Additionally, cells were treated with either α-LIF (at 4 ng/mL, 
40 ng/mL, and 0.4 μg/mL) or α-gp130 (at 50 ng/mL, 0.5 μg/mL, and 5 μg/mL) neutralizing 
antibodies as indicated. Following treatment, whole cell lysates were collected and analyzed 
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by immunoblot for pSTAT3 and total STAT3. E) Quantification of apoptosis as detected by 
TUNEL positive staining in serum-starved HC11/R1 cells after 20 hours of treatment with 30 
nM B/B or ethanol. Cells were also treated with either 2 μM Doxorubicin or saline and either 
4 μM Stattic or its DMSO solvent. Five representative images of each treatment were taken, 
and all cells were counted using DAPI to identify nuclei. TUNEL positive cells in each picture 
were also counted, and percent TUNEL positive cells was determined. Results are shown as 
average percent TUNEL positive cells relative to total cell number. Experiments were 
performed three individual times, and cells were counted in a blinded manner. Error bars 
represent s.e.m. (**P<0.01, ****P<0.001) 
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3.4 Discussion 
While TNBCs represent only approximately 20% of all breast cancers, 
they account for a disproportionate number of breast cancer-related deaths [50, 
319]. Because they do not express HRs or HER2, they do not respond to 
endocrine therapy or HER2-based therapies. Instead, the typical course of 
treatment for TNBCs involves various regimens of chemotherapies, which non-
specifically induce apoptosis. There are several currently used chemotherapeutic 
agents [50, 51, 320, 321]. In the present study, we concentrated on the 
anthracycline-based chemotherapy drug, Doxorubicin, which is often used in 
both adjuvant and neoadjuvant settings [51, 322-324]. Intercalation of 
Doxorubicin into DNA induces double-stranded breaks, which when not properly 
repaired ultimately results in cell death. Interestingly, while patients harboring 
TNBCs do seem to respond relatively well to chemotherapies, this group of 
tumors continues to have the worst prognosis of all breast cancers [78, 325]. 
Patients with TNBCs have significantly worse disease-free survival than patients 
with non-TNBCs, and following disease recurrence, patients with TNBCs have 
significantly worse overall survival than patients without TNBCs with shorter time 
from recurrence to death [325-327]. Additionally, TNBC recurrence often occurs 
at distant rather than local sites [328]. Because recurrent metastatic TNBCs 
result from not achieving pCR and correspond to resistance of chemotherapeutic 
treatment, much work is being done to identify alternative targets in TNBCs that 
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will either increase the number of patients achieving pCR or decrease 
chemoresistance.  
Recently, FGFR1 has been implicated as a potential target in TNBCs. 
Work has been done demonstrating that inhibition of FGFR signaling via the 
small molecule inhibitor, PD173074, in a number of TNBC cell lines sensitizes 
them to decreased cell survival and increased apoptosis [123]. Using siRNA 
directed against FGFR1 also resulted in decreased survival of a TNBC cell line 
[123]. Furthermore, activation of iFGFR1 in vitro has previously been shown to 
reduce the number of cells undergoing apoptosis [128]. We hypothesized that 
FGFR1 activation promotes chemoresistance of TNBCs. In support of this 
hypothesis, it has recently been demonstrated that FGFR1 signaling appears to 
drive endocrine resistance in FGFR1-amplified, ER+ breast cancer cell lines 
[121]. Additionally, another FGFR, FGFR4, has been shown to be upregulated in 
Doxorubicin-treated breast cancer cell lines, whereby it acts to promote 
chemoresistance [329]. We presently verify that iFGFR1 activation in the mouse 
mammary epithelial cell line HC11/R1 decreases apoptosis and further 
demonstrate that iFGFR1 activation confers significant inhibition of apoptosis 
compared to ethanol-treated controls when these cells are treated with the 
chemotherapy Doxorubicin. This effect is at least in part driven by FGFR1-
induced expression of secreted factors because HC11 cells incubated in 
conditioned media from iFGFR1-activated HC11/R1 cells are also protected from 
Doxorubicin-mediated cell death. Moreover, the FGFR-dependent TNBC cell line, 
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Hs578T, undergoes significantly more Doxorubicin-stimulated apoptosis when 
also treated with the FGFR small molecule inhibitor, PD173074. Alternatively, 
bFGF treatment of serum-starved Hs578T cells significantly inhibits Doxorubicin-
induced cell death. We also find that mice transplanted with HC11/R1 cells into 
cleared mammary fat pads and treated with B/B to activate iFGFR1 have 
significantly smaller tumor burden when given both Doxorubicin and PD173074 
as compared to control mice. Tumors in control mice exhibit continual growth, 
while the tumors in mice treated with both Doxorubicin and PD173074 shrink in 
size. Furthermore, these combined treatment tumors have significantly more 
cells undergoing apoptosis than control tumors. Mice treated with only 
Doxorubicin have intermediate tumor size and number of cells undergoing 
apoptosis compared to control or Doxorubicin/PD173074 combination-treated 
mice. Interestingly, inhibition of iFGFR1 with PD173074 alone did not increase 
levels of apoptosis as compared to control treatment animals, although they had 
tumor burden similar to Doxorubicin-only treated animals. It is possible that the 
level of proliferation or angiogenesis differs between the treatment groups as well 
and are currently under investigation. Together these results indicate that FGFR1 
signaling can promote chemoresistance and that inhibiting FGFR signaling can 
increase chemoresponsiveness and apoptosis both in vitro and in vivo.  
Acquisition of chemoresistance is thought to arise through the stem cell 
population. Although the vast majority of tumor cells are in a differentiated state, 
it has been proposed that there exists within the tumor a small number of 
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undifferentiated cancer stem cells or cancer-initiating cells [330, 331]. Studies 
have demonstrated that cancer stem cells are insensitive to chemotherapies and 
that chemotherapy treatment ultimately enriches for the cancer stem cell 
population while the bulk of the tumor responds to chemotherapy and undergoes 
apoptosis [84, 86-88]. Recently, the EGFR ligand AREG has been implicated in 
mammary stem cell maintenance and was shown to be essential for 
mammosphere formation of the mammary epithelial cell line, COMMA-D β-geo 
[155]. We have previously shown that AREG is significantly upregulated following 
iFGFR1-activation and subsequently activates EGFR [318]. In the present study, 
we show that treatment of HC11 cells with rmAREG decreases Doxorubicin-
mediated apoptosis as compared to PBS-treated control cells. Inhibition of EGFR 
with the small molecule inhibitor erlotinib, however, abolishes this 
chemoresistance. Studies attempting to identify factors that are consistently 
expressed in TNBCs have demonstrated that EGFR and cytokeratin 5/6 are 
positive markers that reliably distinguish the set of basal-like TNBCs. This set of 
five markers (EGFR+, cytokeratin 5/6+, ER-, PR-, HER2-) has been designated 
the Core Basal group. The Core Basal group of TNBCs has been found to have 
poorer prognosis than TN basal-like breast cancers that do not express EGFR 
[68, 73]. Our results suggest that EGFR signaling might also mediate 
chemoresistance, thereby resulting in worse patient prognosis in EGFR+ TNBCs, 
and strengthen the hypothesis that EGFR represents a good therapeutic target 
for TNBCs. 
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We previously demonstrated that FGFR1-induced tumorigenic 
phenotypes, such as increased proliferation and migration, require autocrine 
EGFR activation [318]. In this study, we verified that FGFR1 and EGFR are 
expressed in the same TNBC cell lines as detected via immunoblotting of a small 
panel of TNBC cell lines. In iFGFR1-activated HC11/R1 cells treated with 
Doxorubicin, we found that also inhibiting EGFR with erlotinib resulted in a 
significant, but moderate, increase in apoptosis. Because EGFR is activated via 
soluble ligands, we also incubated HC11 cells with HC11/R1 conditioned media. 
HC11 cells incubated in iFGFR1-activated conditioned media and treated with 
Doxorubicin also had a limited increase in apoptosis when erlotinib was added to 
inhibit EGFR signaling. Together, these data suggest that FGFR1 does, at least 
in part, signal through EGFR to stimulate chemoresistance. However, these 
results also indicate that FGFR1 most likely mediates chemoresistance by 
activating multiple downstream effector molecules. Therefore, while EGFR 
appears to be an important mediator of chemoresistance, these results suggest 
that in TNBCs that express both FGFR1 and EGFR, inhibition of FGFR1 might 
be the more beneficial therapeutic strategy. Further studies will need to be 
conducted to fully understand the signaling axis between FGFR1 and EGFR in 
TNBCs. 
Because FGFR1 appears to activate more than one factor to mediate 
chemoresistance, we also investigated the role of STAT3 in FGFR1-stimulated 
chemoresistance. STAT3 has previously been identified to mediate 
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chemoresistance in breast cancer cell lines [282-284]. Notably, STAT3 is 
activated in the TNBC cell line, MDA-MB-231, and inhibition of STAT3 in these 
cells results in increased sensitivity to Doxorubicin [283]. While STAT3 is 
constitutively activated in 50-60% of all breast cancers, it has not yet been 
specifically linked to breast cancers harboring an FGFR1 amplification. In the 
present study, we demonstrate that iFGFR1 activation in HC11/R1 cells results in 
activated STAT3 as detected via immunoblot. Moreover, we show that activating 
FGFR signaling in the TNBC cell line, Hs578T, also stimulates STAT3 activation. 
Notably, STAT3 activation in both cell lines first occurs at the same time point of 
2 hours post-FGFR signaling activation. Interestingly, we did not detect 
phosphorylated STAT3 at 5, 10, 15, 30, or 60 minutes post-FGFR signaling 
activation (data not shown), suggesting that STAT3 is not directly activated by 
binding to FGFR1. This result is in stark contrast to another study demonstrating 
that STAT3 directly binds to and is activated by FGFRs [332]. One possible 
explanation for this discrepancy is that activated FGFR1 does directly induce 
STAT3 activation, but at very low levels in the cell lines we used. It is also 
possible that FGFR1 mediates STAT3 activation in multiple ways, and direct 
activation is not the predominant mode in the cell lines used in this study. 
In support of indirect activation of STAT3 by FGFR1, we show that 
inhibiting either LIF or gp130 with neutralizing antibodies blocks phosphorylation 
of STAT3 in a dose dependent manner in iFGFR1-activated HC11/R1 cells. 
STAT3 was originally discovered as a downstream effector molecule of IL-6 
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signaling, and subsequent studies have demonstrated that multiple cytokines, 
including IL-6, LIF, and OSM can activate gp130/JAK and ultimately stimulate 
STAT3 activation in the normal mammary gland or in breast cancer cell lines 
[233, 262, 263, 270-272]. We show here that iFGFR1 activation significantly 
induces expression of LIF, but LIF is also secreted by immune cells such as 
macrophages. It has previously been shown that iFGFR1 activation in the 
mammary gland recruits macrophages to the sites of prolonged iFGFR1 
signaling [129]. While most TNBCs fall into the basal-like subtype, a number of 
TNBCs can be classified as claudin-low tumors. One proposed feature of 
claudin-low tumors is high levels of infiltrating immune cells [60]. It would be 
interesting to determine if FGFR1-stimulated activation of STAT3 also occurs in 
claudin-low tumors and whether activation of STAT3 in epithelial cells is also 
mediated by infiltrating macrophages.  
We also show that direct inhibition of STAT3 via the small molecule 
inhibitor, Stattic, abolishes the block in Doxorubicin-treated, iFGFR1-activated 
HC11/R1 cells in vitro. These data suggest that FGFR1-stimulated 
chemoresistance is largely mediated through STAT3 activation. As STAT3 is a 
transcription factor, further studies will need to be conducted to determine which 
genes STAT3 regulates in FGFR1-amplified breast cancers. Studies have shown 
that STAT3 directly induces increased Survivin expression, which is a strong 
mediator of cell survival [264, 269, 281]. Other well-known targets of STAT3 
activation include cell cycle regulators, like Cyclin D1 and c-myc, and anti-
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apoptosis factors such as B cell CLL/lymphoma-2 (BCL-2), BCL-2-related gene, 
long isoform (BCL-xL), and myeloid cell leukemia 1 (MCL-1) [269, 275, 276, 282]. 
Moreover, while we directly inhibited STAT3, other studies have demonstrated 
that indirect inhibition of STAT3, by inhibiting JAKs for example, results in 
analogous phenotypes as direct inhibition of STAT3 [266, 272, 277, 282, 283]. 
Further studies might focus on whether gp130 or JAKs represent good targets for 
therapeutic intervention in FGFR1-amplified breast cancers. 
We demonstrate in this study that FGFR1 signaling stimulates 
chemoresistance of Doxorubicin-treated TNBCs. While STAT3 activation 
appears to be the predominant mediator of FGFR1-induced chemoresistance, 
EGFR activation is also involved in this process. Further studies will need to be 
conducted to examine whether inhibiting STAT3 in vivo increases Doxorubicin 
chemosensitivity and to what extent STAT3 activation and FGFR1 amplification 
correlate in human breast cancer tumor samples. 
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Chapter 4: FGFR1-induced soluble factors in 
mammary gland tumorigenesis and 
chemoresistance: What we know and where we 
could go. 
 
4.1 Discussion and Future Directions 
Amplification of the genomic locus of fibroblast growth factor receptor 1 
(FGFR1) occurs in approximately 10% of all breast cancers [114-117]. While 
multiple amplicons have been identified from this region, the amplicon containing 
FGFR1 correlates with increased FGFR1 gene and protein expression [114, 116, 
119, 121, 122]. Moreover, this FGFR1-containing amplicon is found in patients 
with decreased overall and metastasis-free survival and increased development 
of distant metastases, indicating that FGFR1 might prove to be a valuable 
therapeutic target for these patients [116, 119-121]. As such, an early phase 
clinical trial is currently underway to examine the benefits of adding the FGFR 
inhibitor AZD4547 to exemestane treatment of patients with FGFR1 amplification 
in ER+ breast cancers (Safety and Efficacy of AZD4547 in Combination With 
Exemestane Versus Exemestane Alone in ER+ Breast Cancer Patients, NCI 
Clinical Trial Protocol ID: D2610C00003 2010-021220-10, NCT01202591, NCI 
Clinical Trials Database). Further examination of the downstream effects of 
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amplification and overexpression of FGFR1 could lead to identification of novel 
factors for targeted therapies for patients with the FGFR1 amplification, as there 
are currently no FGFR1 specific therapies. Difficulty in specifically targeting 
FGFR1 stems from the complex nature of the FGF family. There are four FGFRs, 
and alternative splicing ultimately generates seven FGFRs that are highly 
homologous within the kinase domains [91, 93-96]. Additionally, there are 22 
FGF ligands, none of which exclusively activates FGFR1 [92, 93]. Therefore, to 
investigate FGFR1 signaling, we use an inducible FGFR1 (iFGFR1) system in 
our studies. 
While the FGFR1 kinase domain was retained in the iFGFR1 system, the 
extracellular ligand binding and transmembrane domains were replaced with a 
myristylation sequence to tether the kinase domain to the plasma membrane 
[127]. Without the ligand binding domain, endogenous FGF ligands cannot bind 
or induce dimerization of the receptor. Instead, dimerization of the iFGFR1 
occurs via treatment with the synthetic molecule originally named AP20187 (AP) 
and then renamed B/B, which binds to an intracellular dimerization domain 
affixed to the kinase domain [127]. HC11 mouse mammary epithelial cells were 
retrovirally transduced to stably express the iFGFR1 construct (called HC11/R1 
cells), and extensive characterization of the iFGFR1 system was performed to 
verify that iFGFR1 behaves in a similar manner to endogenous FGFR1 [127, 
128]. In addition to the HC11/R1 in vitro system, a transgenic mouse line was 
created in which the iFGFR1 construct is under the control of the mouse 
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mammary tumor virus (MMTV) promoter [127]. Therefore, the MMTV-iFGFR1 
transgenic animals express iFGFR1 primarily in mammary epithelial cells. To 
examine FGFR1 signaling on a global scale, microarrays were previously 
performed on RNA isolated from HC11/R1 cells (KLS unpublished data) or from 
mammary glands taken from MMTV-iFGFR1 mice [129]. Numerous genes were 
found to be dysregulated in the iFGFR-activated samples as compared to the 
ethanol-treated control samples, and studies are currently focused on 
investigating several of these factors. 
Two of the most highly upregulated molecules in the iFGFR1-activated 
samples are amphiregulin (AREG) and epiregulin (EREG). These ligands were of 
great interest to us because both AREG and EREG belong to the EGFR family of 
ligands and, in their mature protein state, are soluble factors. Moreover, both 
ligands have been identified in human breast cancers prior to our studies. 
Notably, both ligands appear to correlate with advanced disease state or more 
aggressive breast tumors [169, 179, 180, 197]. Studies using mouse models and 
human breast cancer cell lines have shown that both AREG and EREG stimulate 
mammary tumor invasion and that AREG expression further promotes 
proliferation and tumor growth [138, 174-178, 198, 199].  
In the present work, we confirm that iFGFR1 activation significantly 
increases AREG and EREG expression. Using quantitative reverse transcription-
PCR (qRT-PCR), significant induction of both Areg and Ereg transcripts is 
detected within as little as 30 minutes of AP treatment of serum-starved HC11/R1 
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cells, and increased transcript levels are sustained for at least four hours after 
iFGFR1-activation. Areg and Ereg transcripts are also upregulated in MMTV-
iFGFR1 mouse mammary glands following activation of iFGFR1 via AP 
intraperitoneal (i.p.) injections. Interestingly, significant induction of Areg 
transcripts occurs before significant induction of Ereg transcripts in vivo, 
suggesting that there may be some sort of positive feedback loop in the 
mammary gland. Because much less is known about EREG gene regulation, 
future studies could focus on examining if Areg and Ereg are regulated by the 
same factors and if not, what factors do regulate EREG expression. 
Immunohistochemistry (IHC) analysis of the fourth inguinal mammary glands of 
iFGFR1-activated MMTV-iFGFR1 animals shows that AREG and EREG are also 
upregulated at the protein level. Because AREG and EREG exist as 
transmembrane precursor proteins, we further demonstrate that both ligands are 
cleaved into their mature, soluble forms via ELISA analysis performed using 
conditioned media from serum-starved HC11/R1 cells treated with AP. These 
results are important because they demonstrate that AREG and EREG are not 
just upregulated at the transcript level and then degraded nor are they 
perpetually expressed in their precursor forms. These results also indicate that 
the enzymes responsible for releasing AREG and EREG from the plasma 
membrane are expressed in the HC11/R1 cells. The a disintegrin and 
metalloprotease (ADAM) enzymes have previously been shown to cleave AREG 
and EREG sheddase [107, 164-166]. Future studies could focus on verifying that 
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ADAM proteins are responsible for cleaving AREG and EREG in our system and 
examining how inhibition of the AREG and EREG sheddase(s) affects FGFR1-
mediated tumorigenesis. 
Additionally, we show that upregulation of AREG and EREG occurs in a 
human breast cancer cell line. AREG and EREG transcripts are detectable 4 
hours after basic (b)FGF treatment of serum-starved MCF7 cells, and transcript 
levels remain increased for at least 24 hours after FGFR signaling is stimulated 
with bFGF. Using ELISA analysis, we find that soluble AREG is significantly 
upregulated in the conditioned media of bFGF-treated serum-starved MCF7 cells 
as compared to the no treatment control conditioned media. These results 
confirm that AREG is translated into mature protein that is cleaved from the 
plasma membrane in a human breast cancer cell line. It is of importance to note 
that MCF7 cells are ER+ and PR+ [333]. In the normal developing mammary 
gland, AREG expression is directly mediated by estrogen receptor α (ERα), and 
it has been found that AREG expression often correlates with ER+ and 
progesterone receptor (PR)+ status in breast cancers [145, 157, 172, 173]. 
Because hormone receptor (HR)+ breast cancers generally fall into the luminal A 
and luminal B breast cancer subtypes, it would be interesting to determine if 
AREG is expressed in multiple breast cancer subtypes and whether AREG is 
more highly expressed in luminal A and/or B tumors than in other breast cancer 
subtypes [55, 57, 60]. Moreover, if AREG is found to be most highly expressed in 
the luminal tumors, future studies could be focused on determining if AREG can 
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be used as an indicator of outcome for patients with luminal tumors or as an 
indicator of response to endocrine therapies, which is the common treatment for 
HR+ breast cancers. However, while MCF7 cells are ER+ and PR+, the HC11/R1 
cells are ER- and PR-. Therefore, AREG expression could be mediated by 
different factors between these two cell lines. Other factors known to regulate 
AREG expression include cyclic AMP (cAMP), specificity protein 1, and Wilms’ 
tumor suppressor [132, 140-144]. Future studies could focus on determining if 
any of these factors regulate AREG in ER- breast cancers or, if they do not, on 
identifying which factors do regulate AREG expression in ER- breast cancer. 
While AREG usually positively correlates with HR expression in breast cancers, it 
has been shown that EREG is typically associated with HR- breast cancers [172]. 
Therefore, future studies could examine if AREG and EREG are downstream 
targets of FGFR1 in different types of breast cancers or if they are always co-
expressed in FGFR1-amplified tumors. Alternatively, they may be differentially 
regulated, with AREG more highly upregulated in ER+ FGFR1-amplifed breast 
cancers while EREG is more highly expressed in ER- FGFR1-amplified breast 
cancers. 
Because of their nature as EGFR ligands, upregulation of AREG and 
EREG suggests that EGFR signaling is stimulated downstream of FGFR1 
activation. Immunoblot analysis of multiple tyrosine residues within the EGFR 
kinase domain confirmed that in HC11/R1 cells treated with B/B to activate 
iFGFR1, EGFR phosphorylation is increased as compared to ethanol-treated 
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HC11/R1 control cells. While the residues we assessed are commonly 
phosphorylated when EGFR is activated, there are several other EGFR kinase 
domain tyrosine residues [334, 335]. Studies have found that different ligands 
can induce different phosphorylation patterns of the various tyrosines [334]. 
Future studies aimed at determining whether AREG stimulates a different EGFR 
phosphorylation signature than EREG or other EGFR ligands and whether these 
different phosphorylation patterns result in activation of different downstream 
signaling molecules could result in the development of more specific and less 
toxic EGFR inhibitors. Moreover, these results indicate that EGFR is activated in 
mammary epithelial cells subsequent to FGFR1 activation. Conversely, in the 
normal developing mammary gland, epithelial EGFR is dispensable, while 
stromal EGFR is required, for proper mammary gland development [107, 167]. 
Studies using in vitro co-culture experiments or in vivo tumor models could 
examine whether stromal EGFR is activated and involved in promoting FGFR1-
amplified mammary tumorigenesis. Furthermore, if EGFR is activated in tumor 
stromal cells, it would be important to understand how EGFR activation then 
mediates signaling back to the epithelial cells of the tumors.  
We also show that treatment of serum-starved HC11 cells with either 
recombinant mouse (rm)AREG or rmEREG stimulates ERK1/2 activation and 
significantly increases migration and proliferation. Addition of the EGFR kinase 
inhibitor, erlotinib, to rmAREG- or rmEREG-treated HC11 cells reduces ERK1/2 
activation and significantly inhibits migration and proliferation back to levels 
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comparable to control cells. Additionally, while iFGFR1 activation of HC11/R1 
cells also promotes increased ERK1/2 activation, migration, and proliferation, we 
demonstrate that these processes are partially but significantly inhibited when 
AP-treated HC11/R1 cells are also treated with erlotinib. Taken together, these 
results indicate that FGFR1-induced cellular migration and proliferation and 
ERK1/2 activation are at least in part mediated through AREG- and/or EREG-
stimulated EGFR signaling. Because erlotinib treatment cannot completely inhibit 
the FGFR1-induced cellular migration and proliferation and ERK1/2 activation, 
studies are currently focused on determining what other pathways, besides 
EGFR signaling, are involved in promoting FGFR1-induced tumorigenesis. 
Additionally, while uncontrolled proliferation and an ability to migrate are 
hallmarks of cancer, there are other cellular processes, which AREG and/or 
EREG have been shown to mediate, that are required for tumor progression. For 
example, breast cancer cell lines treated with exogenous AREG have increased 
expression of genes known to promote invasion, such as matrix metalloprotease 
9 (MMP-9), and other studies have shown that using shRNA directed against 
AREG in breast cancer cells reduces invasion into a Matrigel matrix in vitro [138, 
174, 177, 178]. EREG has also been shown to be essential for breast cancer 
cells to intravasate, extravasate, and colonize in the lung, and thus, like AREG, is 
a regulator of invasion [198]. Accordingly, studies examining the role of AREG- 
and/or EREG-stimulated EGFR activation in promoting processes such as 
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invasion of or angiogenesis in FGFR1-amplified tumors should be performed to 
more thoroughly understand the FGFR1/EGFR signaling axis. 
While inhibition of EGFR ultimately abrogates the effects of AREG 
upregulation, we also wanted to determine if directly targeting AREG was a 
valuable therapeutic strategy. We focused on AREG because other studies have 
successfully used shRNA directed against AREG to inhibit processes like breast 
cancer invasion and we consistently see much higher levels of AREG protein in 
iFGFR1-activated HC11/R1 conditioned media than EREG [176, 178]. Therefore, 
HC11/R1 cells were retrovirally transduced to stably express shRNA directed 
against Areg. However, knockdown of Areg did not inhibit the ability of these cells 
to undergo increased proliferation or migration when treated with B/B (data not 
shown). These results may be a consequence of incomplete Areg knockdown or 
redundancy amongst the EGFR ligands. While these data do not support the 
hypothesis that AREG would be a good target for directed therapies in FGFR1-
amplified breast cancer, these cells could be used to evaluate other potential 
roles of AREG in FGFR1-amplified breast cancers. For instance, studies have 
shown that AREG overexpression in mammary epithelial cells leads to altered 
EGFR regulation [336]. While EGFR was rapidly internalized and degraded 
following EGF stimulation, there was prolonged EGFR localization at the plasma 
membrane and decreased phosphorylation at tyrosine 1045 following AREG 
stimulation [336]. Phosphorylation of EGFR tyrosine residue 1045 marks EGFR 
for degradation as it is the binding site for c-Cbl, the E3 ubiquitin ligase 
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responsible for targeting EGFR for degradation [337, 338]. Future work could use 
the HC11/R1 cells expressing Areg shRNA to examine whether EGFR signaling 
is aberrantly prolonged following FGFR1 activation or to study the rate of EGFR 
degradation in our system. Furthermore, AREG activation of EGFR appears to 
stimulate NFkB, which in turn induces expression of IL-1 in human breast cancer 
cell lines [339]. Because IL-1 is a cytokine, these results imply that AREG could 
be involved in mediating immune cell function or recruitment in mammary tumors. 
Investigation of these alternative functions of AREG would ultimately result in a 
better understanding of AREG signaling in FGFR1-amplified breast cancers. 
To expand upon our in vitro results showing that FGFR1 activation 
requires EGFR signaling to promote cell migration and proliferation, we 
performed two in vivo studies using the MMTV-iFGFR1 transgenic mice. In the 
first study, six week old MMTV-iFGFR1 mice were given erlotinib via oral gavage 
for three consecutive days and AP i.p. injections on the second day of erlotinib 
treatment to activate iFGFR1. This method of concurrent iFGFR1 activation and 
erlotinib treatment allows us to analyze the role of EGFR signaling in FGFR1-
mediated tumor initiation. In the second study, we activated iFGFR1 in six week 
old MMTV-iFGFR1 mice prior to five consecutive days of erlotinib oral gavage 
treatment. By activating iFGFR1 before erlotinib treatment, we can analyze how 
inhibiting EGFR effects established aberrant FGFR1 signaling in the mammary 
gland. At the end of each study, mice were injected with BrdU and sacrificed, and 
the fourth inguinal mammary glands were harvested, fixed, and sectioned for 
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further investigation. In line with previous observations from studies using MMTV-
iFGFR1 transgenic mice, we observed a significant increase in aberrant ductal 
epithelial cell lateral budding in AP-treated animals from both studies as detected 
by hematoxylin and eosin (H&E) staining [127, 129]. Importantly, erlotinib 
treatment significantly reduced the number of ductal structures exhibiting this 
lateral budding, and in the second study, erlotinib treatment also significantly 
reduced the severity (as determined by number of buds) of the budding 
phenotype in the ducts that do exhibit aberrant budding. Furthermore, 
immunofluorescence (IF) staining to detect BrdU demonstrated that iFGFR 
activation significantly increases proliferation, while erlotinib treatment of AP-
treated mice significantly reduces proliferation. Taken together, these results 
demonstrate that EGFR signaling is required to promote FGFR1-mediated 
tumorigenic phenotypes in vivo. Although the MMTV-iFGFR1 mice provide a 
good model for studying tumor initiation, future studies should be directed at 
determining the benefit of erlotinib treatment in FGFR1-amplified mammary 
tumors. While the data presented thus far have concentrated on proliferation and 
migration in FGFR1-activated cells, many other cellular processes are co-opted 
during tumor progression [340]. Therefore, it would be of value to examine the 
effects of EGFR signaling on other tumorigenic pathways, such as angiogenesis 
and metastasis, of FGFR1-amplified tumors. Additionally, previous work has 
shown that EGFR mediates mammary tumor cell metastasis to the bone and that 
FGFR1-amplification correlates with increased distant metastasis [119, 120, 205, 
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341]. It would be interesting to investigate whether FGFR1-amplified tumors most 
commonly metastasize to the bone. Moreover, studies using human breast 
cancer specimen will need to be performed to determine whether co-expression 
of FGFR1, AREG, EREG, and EGFR occurs in human breast cancers. 
The data described thus far demonstrate that FGFR1 signaling promotes 
mammary tumorigenesis by upregulating AREG and EREG which then activate 
EGFR signaling. These studies have primarily focused on FGFR1 signaling 
during initial stages of tumor development, but FGFR1 signaling is likely involved 
in all stages of mammary tumorigenesis. Other studies investigating the role of 
FGFR1 in breast cancers have determined that FGFR1 signaling can mediate 
endocrine therapy resistance and is also crucial for survival of several triple 
negative breast cancer (TNBC) cell lines both in vitro and in vivo [121, 123]. In 
line with these results, it has also been shown that AREG and EGFR are 
involved in therapeutic resistance of breast cancers [145, 181, 182]. These 
results, along with the fact that TNBCs are currently treated with chemotherapies, 
such as the anthracycline-based chemotherapy Doxorubicin, led us to 
hypothesize that FGFR1 signaling mediates chemoresistance [50, 51, 320, 321]. 
In support of this hypothesis, it has previously been shown that iFGFR1 
activation decreases the number of cells undergoing apoptosis [128]. 
In the present study, we confirm that activation of iFGFR1 in serum-
starved HC11/R1 cells significantly reduces apoptosis compared to ethanol-
treated control cells as assessed by ApoTox-Glo and TUNEL assays. Moreover, 
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while Doxorubicin significantly increases apoptosis of serum-starved ethanol-
treated HC11/R1 cells, there is significantly less Doxorubicin-induced apoptosis 
in serum-starved B/B-treated HC11/R1 cells. These results demonstrate that 
iFGFR1 signaling confers resistance to a commonly used chemotherapeutic. We 
further demonstrate that FGFR1-mediated chemoresistance involves the 
secretion of soluble factors because serum-starved Doxorubicin-treated HC11 
cells incubated in conditioned media from B/B-treated HC11/R1 cells undergo 
significantly less apoptosis than serum-starved Doxorubicin-treated HC11 cells 
incubated in conditioned media from ethanol-treated HC11/R1 cells. Moreover, 
these results are consistent with results from the human TNBC cell line, Hs578T. 
Serum-starved Hs578T cells treated with bFGF to stimulate FGFR signaling 
undergo significantly less apoptosis than no treatment control serum-starved 
Hs578T cells. Like the HC11/R1 and HC11 control cells, serum-starved Hs578T 
control cells undergo significantly more apoptosis when given Doxorubicin, while 
bFGF-induced FGFR signaling reduces the amount of apoptosis detected in 
Doxorubicin-treated serum-starved Hs578T cells. Conversely, Hs578T cells 
treated with the FGFR inhibitor PD173074 undergo significantly more apoptosis 
than Hs578T cells treated with the PD173074 solvent control, DMSO. Hs578T 
cells treated with both PD173074 and Doxorubicin have a significant increase in 
apoptosis. However, Hs578T cells treated only with Doxorubicin undergo 
significantly less apoptosis than Hs578T cells treated with both Doxorubicin and 
PD173074. In line with these in vitro results, we show that inhibition of FGFR 
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signaling in an orthotopic transplant model of iFGFR1-activated mammary 
tumorigenesis also sensitizes tumor cells to Doxorubicin-induced apoptosis. Mice 
treated with both Doxorubicin and PD173074 have significantly less tumor 
burden than control mice. Moreover, tumors actually shrink in size once the 
combination therapy is started, while control tumors undergo continual growth. 
Based on TUNEL analysis of tumor sections, we observe a significant increase in 
apoptosis in tumors treated with both Doxorubicin and PD173074 as compared 
to control treatment tumors. Taken together, these data strongly support the 
hypothesis that FGFR1 signaling prevents chemotherapy-induced apoptosis. It 
would be interesting to determine whether FGFR1-mediated chemoresistance is 
restricted to the class of anthracycline chemotherapies or if FGFR1 universally 
confers chemoresistance. Moreover, because chemotherapy regimens often 
involve multiple chemotherapy drugs, future studies could be directed at 
determining if FGFR1-mediated chemoresistance can be overridden in a multi-
drug treatment plan. 
Due to our earlier results showing that EGFR is required downstream of 
FGFR1 to promote tumorigenic phenotypes and other reports demonstrating that 
EGFR is involved in mediating chemoresistance, we investigated the involvement 
of EGFR signaling in FGFR1-mediated chemoresistance by first examining 
whether FGFR1 and EGFR are expressed in the same TNBC cell lines. 
Immunoblot analysis of a small panel of TNBC cell lines demonstrated that 
FGFR1 and EGFR are co-expressed in the cell lines tested. Clearly a more 
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extensive examination will need to be conducted to discern whether FGFR1 and 
EGFR co-expression is a common occurrence in TNBCs. Furthermore, although 
the focus of the current study is TNBCs because these tumors are treated with 
chemotherapy regimens, future work could explore whether FGFR1 and EGFR 
co-expression is confined to TNBCs. We further show that serum-starved HC11 
cells treated with rmAREG to stimulate EGFR activation undergo significantly 
less apoptosis than serum-starved PBS-treated control HC11 cells. EGFR 
activation significantly inhibits Doxorubicin-induced apoptosis of serum-starved 
HC11 cells although Doxorubicin significantly increases apoptosis of serum-
starved PBS-treated HC11 cells. Interestingly, in serum-starved PBS-treated 
HC11 cells treated with both erlotinib and Doxorubicin, there is a significant 
increase in apoptosis. Because EGFR is not activated in these cells, future 
studies will need to be conducted to determine why erlotinib confers increased 
cell death when given in conjunction with Doxorubicin when erlotinib treatment 
alone does not increase apoptosis of PBS-treated serum-starved HC11 cells. 
Regardless, addition of erlotinib to serum-starved HC11 cells treated with both 
rmAREG and Doxorubicin abolishes the apoptosis inhibition seen in serum-
starved HC11 cells treated with both rmAREG and Doxorubicin. Taken together, 
these results indicate that EGFR signaling can mediate chemoresistance and 
that inhibiting EGFR with erlotinib can sensitize cells to Doxorubicin-induced cell 
death. Additionally, because FGFR1 and EGFR are co-expressed in the TNBC 
cell lines tested, these results suggest that FGFR1 might mediate 
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chemoresistance by activating EGFR. Using ApoTox-Glo assay, we find that 
HC11/R1 cells treated with B/B, Doxorubicin, and erlotinib have a moderate 
increase in apoptosis as compared to HC11/R1 cells treated with B/B and 
Doxorubicin. Analogous results were obtained using serum-starved HC11 cells 
incubated in HC11/R1 conditioned media. HC11 cells incubated in conditioned 
media from B/B-treated cells undergo a slight increase in apoptosis when further 
treated with Doxorubicin and erlotinib as compared to only Doxorubicin 
treatment. Future studies should be focused on verifying these results in human 
breast cancer cell lines and with different chemotherapies or combinations of 
chemotherapies. Together, these data suggest that in breast cancers without 
FGFR1 amplification, EGFR signaling can mediate chemoresistance and should 
be further evaluated as a target for increasing chemosensitivity, but in FGFR1-
amplified breast cancers, EGFR is one of multiple downstream factors mediating 
chemoresistance. 
Activation of signal transducer and activator of transcription 3 (STAT3) has 
been shown to correlate with incomplete pathological complete response of 
patients treated with chemotherapies and, thus, correlates with acquisition of 
chemoresistance [264]. Additionally, STAT3 has been identified to promote 
chemoresistance of human breast cancer cell lines, the most notable example 
being STAT3-mediated Doxorubicin chemoresistance of MDA-MA-231 cells [282-
284]. Consequently, in the present study, we investigate STAT3 involvement in 
regulating FGFR1-mediated chemoresistance. Immunoblot analysis of serum-
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starved HC11/R1 cells revealed that in B/B-treated cells, phosphorylation of 
STAT3 is stimulated after 2 hours of iFGFR1 activation but is not detectable in 
ethanol-treated control samples. This iFGFR1-induced activation of STAT3 
continues to occur for at least 24 hours. These results demonstrate that STAT3 is 
regulated by iFGFR1 signaling. Furthermore, these results were verified in the 
Hs578T human TNBC cell line. Activation of STAT3 occurs by 2 hours, and is still 
detectable 24 hours, after bFGF treatment of serum starved Hs578T cells. 
Interestingly, although work from another lab shows that STAT3 directly binds to 
and is activated by FGFRs, the delay from FGFR activation to STAT3 activation 
implies that STAT3 is not directly activated by FGFR1 in our system [332]. 
Supporting our results of indirect activation of STAT3 by FGFR1, several reports 
investigating STAT3 activation in breast cancer cell lines show that STAT3 is 
activated by glycoprotein-130/Janus kinase (gp130/JAK) signaling stimulated by 
cytokine binding to gp130 [270-272]. Additionally, we show that soluble factors in 
conditioned media from iFGFR1-activated HC11/R1 cells can protect HC11 cells 
from Doxorubicin-induced apoptosis. Together, these data suggest that iFGFR1-
induced cytokines might be stimulating activation of STAT3 in our system. In the 
present study, we verify using ELISA analysis that a well-known cytokine inducer 
of STAT3 in the mammary gland, leukemia inhibitory factor (LIF), is significantly 
upregulated in B/B-treated HC11/R1 conditioned media as compared to in 
ethanol-treated HC11/R1 conditioned media [262]. Furthermore, we show that 
inhibition of either LIF or gp130 with neutralizing antibodies effectively blocks 
  141 
STAT3 activation in iFGFR1-activated HC11/R1 cells. Together, these data 
suggest that STAT3 activation is regulated by iFGFR1 signaling through iFGFR1-
induced expression of LIF, which activates gp130. Future studies will need to be 
conducted to determine what other cytokines are induced following iFGFR1 
activation and if other iFGFR1-induced cytokines can activate STAT3. Moreover, 
cytokines are traditionally secreted by immune cells such as macrophages, and 
previous work using MMTV-iFGFR1 transgenic mice has shown that iFGFR1 
activation recruits macrophages to the sites of prolonged iFGFR1 signaling in the 
mammary glands of these mice [129]. Therefore, it would be interesting to 
determine if FGFR1-stimulated activation of STAT3 is also mediated by 
infiltrating macrophages in vivo. Additionally, STAT3 is negatively regulated by 
several factors, including the cytoplasmic suppressors of cytokine signaling 
(SOCS) proteins and the nuclear protein inhibitor of activated STAT (PIAS) [342, 
343]. It would be interesting to examine how expression of these negative 
regulators changes when iFGFR1 is activated. Further work will also need to be 
done to determine what factors are regulated by STAT3 following FGFR1 
activation. Other studies have reported that STAT3 can induce expression of 
several genes, including multiple MMPs, Cyclin D1, and c-myc [269, 276]. Most 
notably for our studies, upregulation of several anti-apoptotic factors, such as B 
cell CLL/lymphoma-2 (BCL-2), myeloid cell leukemia 1 (MCL-1), BCL-2-related 
gene, long isoform (BCL-xL), and Survivin (a member of the Inhibitor of 
Apoptosis family of proteins) has been detected in breast cancer cell lines 
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following STAT3 activation, making them attractive candidates for mediating 
FGFR1-induced chemoresistance [264, 269, 275, 281, 282].  
Importantly, in the present study, we demonstrate that STAT3 activation 
confers Doxorubicin chemoresistance in iFGFR1-activated cells. As we have 
shown before in this work, serum-starved B/B-treated HC11/R1 cells undergo 
significantly less apoptosis when given Doxorubicin than serum-starved ethanol-
treated HC11/R1 cells given Doxorubicin as detected by TUNEL staining. 
Alternatively, we observe that directly inhibiting STAT3 with the small molecule 
inhibitor Stattic in Doxorubicin-treated serum-starved iFGFR1-activated HC11/R1 
cells abolishes this reduction in apoptosis, and these cells undergo apoptosis at 
levels comparable to serum-starved ethanol-treated HC11/R1 cells given 
Doxorubicin with or without Stattic treatment. Future studies will need to be 
directed at determining if these results are consistent in human breast cancer 
cells as well as in an in vivo mouse model of mammary tumorigenesis. Human 
breast cancer samples will also need used to see if FGFR1 and activated STAT3 
are co-expressed in breast cancers, especially in TNBCs. Additionally, while 
clinical trials are currently underway to examine the effects of inhibiting STAT3 in 
other types of cancer, there are currently no clinical trials using STAT3 inhibitors 
in breast cancer patients. The data presented here give credence to the need for 
clinical trials using STAT3 inhibitors in breast cancer patients, especially for 
patients with FGFR1-amplified TNBCs. Moreover, EGFR is a known activator of 
STAT3 in breast cancer cell lines [257, 266, 344]. While we have preliminary 
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data suggesting that EGFR does not mediate activation of STAT3 in iFGFR1-
activated HC11/R1 cells (data not shown), it would be interesting to see if STAT3 
is activated by EGFR in non-FGFR1-amplified breast cancers.  
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4.2 Conclusions 
As summarized in Figure 12, the work presented here shows that FGFR1 
activation significantly upregulates expression of the EGFR ligands AREG and 
EREG at the transcript and protein levels both in vitro and in vivo. AREG and 
EREG then activate EGFR signaling. Notably, EGFR activation is at least in part 
required for FGFR1-induced proliferation and migration and ERK1/2 activation, 
as inhibition of EGFR with the small molecule kinase inhibitor erlotinib 
significantly blocks these processes. Moreover, we show that FGFR1 and EGFR 
are co-expressed in TNBC cell lines and that both FGFR1 and EGFR can 
mediate Doxorubicin chemoresistance. We further show that FGFR1 upregulates 
expression of the cytokine LIF, which then signals through gp130/JAK to activate 
STAT3 in vitro. Directly inhibiting either FGFR1 or STAT3 significantly reduces 
chemoresistance and increases apoptosis in vitro. Furthermore, inhibition of 
FGFR1 with the small molecule inhibitor PD173074 results in increased 
chemosensitivity and apoptosis in a mouse model of mammary tumorigenesis. 
These results are significant because they are the first to show that FGFR1 
signals through EGFR and that FGFR1 mediates chemoresistance through 
activation of STAT3. This study furthers our understanding of FGFR1-amplified 
mammary tumorigenesis and presents alternative factors for targeted therapies 
for patients with FGFR1-amplified breast cancers.  
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Figure 12: Final Model Figure. 
Activation of iFGFR1 via treatment with the B/B homodimerizer results in phosphorylated 
ERK1/2 and ultimately in increased expression of the EGFR ligands, AREG and EREG, and 
the cytokine, LIF. Soluble AREG and EREG can then bind and activate EGFR, leading to 
phosphorylation of ERK1/2 and Akt and expression of Cyclin D1. Functional studies 
demonstrate that activation of EGFR downstream of iFGFR activation results in increased 
cellular proliferation and migration. Alternatively, LIF binding to its cytokine receptor results in 
phosphorylation of STAT3, which subsequently decreases Doxorubicin-induced apoptosis. 
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